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Abbrevations  
  
ii 
 
CA: contrast agent;  
cHANPs: crosslinked hyaluronic acid nanoparticles;  
DOSY: diffusion-ordered nmr spectroscopy;  
DSC: differential scanning calorimetry;  
DVS: divinyl sulphone;  
EE: encapsulation efficacy;  
EMA: european medicines agency;  
FDA: food and drug administration;  
Gd: gadolinium;  
Gd-DTPA: diethylenetriaminepentaacetic acid gadolinium(iii) dihydrogen salt 
hydrate;  
HA: hyaluronic acid;  
HA NPs: hyaluronic acid nanoparticles;  
HLB: hydrophilic-lipophilic balance;  
HyCoS: hybrid core-shell;  
ICP-MS: inductively coupled plasma mass spectrometry;  
IR: inversion recovery;  
ITC: isothermal titration calorimetry;  
LC: loading capability;  
MLS: multiple light scattering;  
MRI: magnetic resonance imaging;  
iii 
 
NaOH: sodium hydroxyde pellets;  
NMR: nuclear magnetic resonance;  
NMRD: nuclear magnetic relaxation dispersion;  
NPs: nanoparticles;  
NSF: nephrogenic systemic fibrosis;  
PC: continuous phase;  
PD: dispersed phase; 
PET: positron emission tomography;  
S80: sorbitan monooleate (span® 80);  
SBM: solomon-bloembergen-morgan;  
SEM: scanning electron microscopy;  
SR: saturation recovery; 
T85: polyoxyethylenesorbitan trioleate (tween® 85);  
TEM: transmission electron microscopy; 
W/O: water in oil.   
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Cancer and cardiovascular diseases are silent killers which cause 
million deaths worldwide every year and this number is expected to triple by 
2035.  
Current diagnostic techniques cannot easily, safely, and effectively detect these 
human body lesions in the early stage, nor can they characterize the lesion 
features. 
In this context, the biological application of nanoparticles is a rapidly developing 
area of nanotechnology that raises new possibilities in the diagnosis and treatment 
of  pathologies. Recently, rational design of a new class of contrast agents (CAs), 
based on biopolymers (hydrogels), have received considerable attention in 
Magnetic Resonance Imaging (MRI) diagnostic field. Several strategies have been 
adopted to improve relaxivity without chemical modification of the commercial 
CAs, however, understanding the MRI enhancement mechanism remains a 
challenge. Here, in order to develop a safe and more efficient MRI CA for 
imaging applications, the basic principles ruling biopolymer-CAs interactions are 
investigated to better understand their influence on the relaxometric properties of 
the CA by adopting a multidisciplinary experimental approach. In addition, the 
effect of the hydration of the hydrogel structure on the relaxometric properties, 
called Hydrodenticity, is used to develop Gadolinium-based polymer nanovectors 
with improved MRI relaxation time. The experimental results indicate that the   
vi 
 
entrapment of metal chelates in hydrogel nanostructures offers a versatile 
platform for developing different high performing CAs for diseases diagnosis. 
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1. Diagnostic imaging in clinical practice  
Historically, our understanding of the different pathologies has been mainly based on 
postmortem examinations of human body or analysis of resected surgical specimens 
from patients. In recent years, there have been many advances in the pathogenesis and 
diagnosis of diseases and nowadays, imaging technology allows to look directly inside 
the human body
1
. 
Imaging science is a dynamic filed and, for more than 50 years, the purpose of 
scientists is to provide a non-invasively approach to visualize anatomical details using 
different energy forms. Initially, imaging innovation was primarily driven by technical 
advances in order to improve image quality and have led to greater use imaging as an 
important tool at all stages of the pathological process, from prevention to post-
treatment follow-up.  In current clinical practice, in fact, several imaging modalities, 
invasive and noninvasive, are available to provide structural and functional information 
to clinicians about tissue and organ physiology. Of these, only  Computed Tomography 
(CT), Magnetic Resonance Imaging (MRI), Single-photon Emission Computed 
Tomography (SPECT) and Positron Emission Tomography (PET) are capable of 
providing 3D data of pathologies anywhere in the human body
2
. Undoubtedly, 
available structural and functional imaging techniques have improved diagnostic 
accuracy, but the choice and applicability of each imaging technique depend not only 
on its diagnostic efficacy, but also on the type of questions being asked. In addition, the 
these diagnostic modalities do not inform clearly on the cellular and molecular 
processes that drive the development of specific pathologies and each of the imaging 
techniques has advantages and limitations in terms of radiation exposure, 
reproducibility, sensitivity, resolution and costs. 
The main benefits, limitations and risks associated with four different types of imaging 
techniques are reported below.  
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1.1 Magnetic Resonance Imaging (MRI)  
MRI is a non-invasive imaging modality that able to acquire 3D tomographical 
information at high spatial and temporal resolution in whole tissue samples (i.e. human 
soft tissues, animals). In contrast to the other medical imaging methods, which expose 
patients to ionizing radiation, MRI uses strong non-ionizing electromagnetic fields in 
the radio frequency range, offers an excellent spatial resolution, is operator 
independent and provides 3D data
3, 4
.  It is mainly used for analysis of heart, brain, and 
nervous system.   Owing to its higher intrinsic soft-tissue contrast, MRI has distinct 
advantages for the detection of distant metastases, especially in the skeleton, the brain, 
soft tissues, and the liver. Compared to other imaging techniques (i.e., nuclear 
medicine techniques), it shows low sensitivity and long acquisition time. Moreover, 
MRI’s susceptibility to artifacts of motion and organ pulsation means that it has certain 
limitations for the detection of specific pathologies.                                  
                               During MRI scans, it is often required the use of contrast 
media, also called contrast agents (CAs), chemical substances injected into the body, in 
order to improve the quality of the MRI analysis and obtain more accurately report on 
abnormality present. 
 
 1.2 Computed Tomography (CT)  
This diagnostic technique uses X-ray to provide cross-sectional, 3D images of internal 
organs, bone, soft tissue and blood vessels. It provides a high temporal and spatial 
resolution and allows to view anatomical details and identify a wide range of disorders 
including carcinomas (lung, liver, kidney, and pancreas), vascular disease, pulmonary 
embolism, skeletal abnormalities, and children-specific conditions, such as congenital 
malformations (heart, kidneys and blood vessels) 5, 6. CT scan can also have a role in 
the determination of surgeries and it can be performed with or without administration 
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of contrast agents (CAs).  Currently, the technical limits of CT is represented by poor 
soft tissue contrast. In addition, unlike MRI, CT exposes patients to high radiation dose   
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and the iodinated CAs utilized for enhancing a specific part of an organ. The radiation 
dose depends on multiple factors (i.e. volume scanned, patient build, scanning time and 
desired resolution)
5
 and creates ions and hydroxyl radicals in the body that interact 
with DNA critically damaging chromosomes. Furthermore, the intravascular 
administration of these agents involves allergic or toxic reactions for patients
7
.  
 
 1.3 Positron Emission Tomography (PET)  
Unlike CT or MRI, which show anatomic detail, Positron Emission Tomography 
(PET) is a nuclear imaging technique and provides quantitative in vivo assessment of 
physiological and biological phenomena. This modality necessitates the injection of a 
small quantity of radioisotopes used as tracers
8
. PET agents provide a better functional 
assessment of diseases than tracers used in current nuclear imaging modalities and one 
of the most used PET agents, for understanding the pathological stages of vascular 
lesion in vivo, is 2-deoxy-2-
18
F-fluoro-D-glucose (
18
F-FDG), a synthetic molecule that 
competes with glucose for uptake into metabolically active cells (ie. inflammatory 
cells), but is not metabolized
9
. The advantage of PET over other imaging modalities, 
such as SPECT (Single Photon Emission Computed Tomography), is represented by 
high spatial resolution and contrast resolution and superior sensitivity that allow 
detection of picomolar tracer concentrations in the arteries
10
. Unfortunately, limited 
spatial resolution (~ 2 mm) means that images must be coregistered with CT or MRI 
for precise anatomical localization of 
18
F-FDG uptake.  
 
 
 1.4 Single Photon Emission Computed Tomography 
(SPECT)  
Single Photon Emission Computed Tomography (SPECT) is a non-invasive nuclear 
imaging technique that provides tomographic images of the distribution of intravenous   
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radiolabeled molecules (radioactive tracers) to detect and track overtime molecular 
changes in the central nervous, cardiovascular, respiratory, and skeletal systems with a 
high degree of confidence
11
.                                           
The radiotracers used in SPECT applications have long half-lives (from a few hours to 
a few days)  and emit gamma rays. On the basis of specific application being 
investigated, different type of radiotracers can be used: Technetium-99m (
99m
Tc, T1/2 
= 6.0 h), Indium-111 (
111
In , T1/2 = 67.3 h), Iodine-123 (
123
I, T1/2=13.3 h) and 
Thallium-201(
201
Tl, T1/2 = 72.9 h)
12
.                              
   Unlike PET, SPECT does not require higher infrastructure cost, but PET 
scans offer a higher spatial resolution and accuracy than SPECT scans (spatial 
resolution: 10 mm). Despite these limitations, SPECT represents the modality of 
choice in cardiac field.  
 
1.5 Imaging and future trends  
The significant improvements in image quality and speed have evolved directly from 
technological advances in the design and construction of new and more efficient 
machines for diagnosis, but spatial resolution represents the main limitation for almost 
of imaging modalities, while sensitivity is limited by radiation dose or other safety 
considerations.  
Nowadays, imaging focus has been moved to contrast agents/probes/biomarkers that 
target specific biological processes. Continuing developments in molecular biology and 
nanotechnology, however, have expanded the area of imaging applications with the 
aim of providing a diagnose diseases earlier (before symptoms are obvious in 
preclinical stages) and more precisely. Moreover, additional structural and functional 
information to clinicians about the site of interest allow delivering the right treatment 
to the patient at the right time. 
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In this context, MRI technology plays a key role and represents the unique technique 
for molecular imaging applications that combines excellent soft tissue discrimination, 
high spatial resolution,  outstanding signal to noise ratio and short imaging times   
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without the use of ionizing radiation.  Nevertheless, this imaging modality is limited by 
its low sensitivity and requires the use of CAs to display clearly the site of interest. 
Next sections highlight the latest knowledge about the role of CAs in MRI applications 
and future research directions based on nanotechnology approaches in diseases 
diagnosis. 
 
2. MRI and Contrast Agents 
In order to improve the sensitivity of MRI by increasing the contrast of the target from 
the background, intravenous administration of diagnostic pharmaceutical compounds, 
as known as contrast agents (CAs), is often required during MRI scans. MRI CA are 
generally categorized as T1 (longitudinal relaxation time) and T2 (transverse relaxation 
time) CA based on their magnetic properties and relaxation mechanisms. Gadolinium 
(Gd
3+
) chelates are effective for increasing T1 relaxation rate (1/T1) and commonly 
used as T1 CA, generating a positive image contrast. Superparamagnetic iron oxide 
nanoparticles (SPIONs) are more effective for increasing T2 relaxation rate (1/T2) and 
commonly used as T2 CA, producing negative image contrast. To date, the majority of 
MRI CA used in clinical practice are Gd
3+ 
chelates, with over 10 million contrast-
enhanced MRI scans on an annual basis, because of their high paramagnetism, 
favorable properties in term of relaxation enhancement, relatively high stability, and 
inertness in the body
13
. They include non-specific extracellular CAs and organ-specific 
CAs, mostly liver-specific CAs. Gadolinium chelates are the most widely used 
extracellular as non-specific contrast agents
14
. 
Gd is a powerful paramagnetic ion with seven unpaired electrons and influences the 
relaxation of nearby water protons. Free ion Gd
3+
 is acutely toxic in vivo owing to its 
tendency to precipitate and be deposited in tissues (primarily in the liver), which 
prolongs its half-life
15-17
; the binding to a chelate complex makes the ion chemically 
inert. After chelation, the rate of renal excretion of the Gd complex is increased several 
times compared with free Gd
18
. These agents differ in a number of properties 
(magnetic properties and biodistribution), some of which may significantly impact   
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their clinical utility, particularly for specific applications
19
. In addition, they can be 
classified into four main categories according to their biochemical structure 
(macrocyclic or linear) and to their charge (ionic or non-ionic)
20
. Despite differences 
among the chelating molecules, they appear to have remarkably similar diagnostic 
efficacies and safety profiles
14
. 
Currently, seven Gadolinium based contrast agents (GBCAs) are approved for clinical 
use in the international market by the U.S. Food and Drug Administration (FDA): 
gadopentetate dimeglumine (gadolinium diethylene triamine pentaacetic acid (Gd-
DTPA), Magnevist®; gadodiamide (gadolinium diethylene triamine penta-acetic acid 
bis-methylamide (GD-DTPA-BMA), OmniScan®; Gadoteridol (Gadolinium-1,4,7- tris 
(carboxymethyl)-10-(2' hydroxypropyl)-1, 4, 7 -10-tetraazacyclododecane (Gd-
HPD03A]), ProHance®; gadoterate meglumine (gadolinium-tetraazacyclododecane 
tetra acetic acid (Gd-DOTA), Dotarem®; gadobenate dimeglumine, gadoversetamide, 
(OptiMARK, Covidien, Dublin, Ireland); gadobutrol
21
.  
They work by altering the intrinsic longitudinal (T1) relaxation times of the water 
protons in the various soft tissues where the agents distribute
22
. These agents are 
characterized by the relaxivity (r1, for T1 contrast agents) which is defined as the 
change in relaxation rate (R1 = 1/T1 in units of s
-1
) of solvent water protons upon 
addition of CA, normalized to the concentration of contrast agent ([CA] in units of 
mM)
23
. This effect includes inner-sphere (from water molecules directly coordinated to 
the Gd) and outer-sphere contributions (from nearby, H-bonded waters) and it is 
described by the Solomon-Bloembergen-Morgan (SBM)
24
 equation. Thus, high 
relaxivity of a CA is critical for effective contrast-enhanced MRI and it is not a 
constant, but depends on various parameters such as applied field, temperature, the 
hydration state of the molecule and the molecular size.  
Current MRI agents require injection of gram quantities of Gd in order to obtain 
satisfactory contrast in the resulting image. For clinical use, the recommended dose for 
GBCAs is typically 0.1–0.3 mmol/kg14. Potential advantages of using Gd chelates at 
higher doses include better lesion enhancement, delineation and detectability of cancer 
pathology. With such large doses required for reasonable image enhancement, current 
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contrast agents are limited to targeting sites where they can be expected to accumulate 
in high concentrations, such as in the bloodstream. In addition, their effectiveness 
remains limited owing to nephrotoxic effects, lack of tissue specificity, low relaxivity 
and short circulation half-lives. These agents have historically been considered safe, 
well tolerated when used at recommended dosing levels and linked to the occurrence of 
nephrogenic systemic fibrosis (NSF) in renal impaired patients
25-27
, but, recently, 
McDonald and coworkers have reported results about progressive Gd deposition in the 
brain, bone and kidneys after repeated intravenous administration of CAs
28, 29
. As a 
result, the Food and Drug Administration (FDA) has alarmed the medical community 
and has recommended healthcare professionals to limit the use of Gd-based CAs unless 
necessary and to report any possible related side effects. Also the European Medicines 
Agency (EMA) confirms recommendations to restrict the use of some linear Gd agents 
used in MRI body scans and to suspend the authorisations of others. 
 
3. Next generation of CAs 
Despite the valuable role of the CAs for MRI, these latest results confirm the need to 
have a biocompatible system able to boost a clinical relevant Gd-chelate without its 
chemical modification. 
Ideally, the next generation agents will be site-specific; much higher relaxivities will 
be required to account for the decrease in concentration that accompanies increased 
tissue specificity. 
There have been significant efforts to design and develop novel GBCAs with high 
relaxivity, low toxicity and specific site binding. The relaxivity of the diagnostic 
pharmaceutical compounds can be increased by proper chemical modification. 
According to SBM theory, it is needed to design a ligand that will enable the complex 
to have a greater number of inner-sphere water molecules (q); an optimally short water 
residence life time (τm); and a slow tumbling rate (τr) while maintaining sufficient 
thermodynamic stability. Indeed, it has been demonstrated that the relaxivity of a Gd 
complex will increase upon slowing down its molecular tumbling (increasing its   
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molecular weight) insofar as its water residence time is close to optimal. Considering 
the aforementioned properties, current commercial CAs have several disadvantages. 
They have only one coordinated water molecule and fast tumbling rates due to their 
small size
30
.  In addition, the toxicity of Gd
3+
 can be reduced by increasing the agents’ 
thermodynamic and kinetic stability, as well as optimizing their pharmacokinetic 
properties. Moreover, the increasing knowledge in the field of genomic and biology 
provides an opportunity for designing site-specific CAs. According to these parameters 
and by exploiting the versatile properties of nano- and bio-materials several 
nanostructured CAs with enhanced relaxivity have been investigated.  
 
4. Nanomedicine and nanocarriers for diagnostic 
applications  
Nanotechnology is defined as the use of materials and structures with novel properties 
and functions obtained from their size which ranges from 1 to 100 nm. Nanomedicine 
is the medical application of nanotechnology and it is a science based on the design 
and development of therapeutics and/or diagnostic vectors on the nanoscale
31
.                  
The main goal of nanomedicine is to delivery agents in a specific and efficient way to 
the site of interest. In general, this can be achieved by different ways of administration, 
such as oral, nasal, transdermal, and intravenous.                                        
Factors that determine nanomaterial design and characterization include size and 
shape, blood half-life, controlled drug release and active targeting of nanovectors
32
. In 
addition, the efficacy of the pharmaceutical compound can be improved and side 
effects reduced by encapsulation or association to some type of nanovector. Indeed, 
through advances made in nanotechnology and materials science, researchers are now 
creating a new generation of CAs that are capable of providing more sensitive and 
specific informations.  In fact, nanoscale manipulation in combination with traditional 
diagnostic methods, provides new sensitive, specific, reproducible and cost effective 
methods for diagnosis of different types of pathology.  
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Extensive libraries of nanostructures, composed of an assortment of different sizes, 
shapes, and materials, and with various chemical and surface properties, have already 
been constructed. The field of nanotechnology is under constant and rapid growth and 
new additions continue to supplement these libraries. Several nanocarriers have been 
approved for clinical use and they are currently used to diagnosis various types of 
cancers
33
. Furthermore, there are several formulations, which are now in various stages 
of clinical trials
34
. 
Clinical aspects related to the use of nano- and biomaterials such as polymer 
nanoparticles, block copolymers structures and liposomes for MRI applications are 
reported below. In addition, taking into account that multimodal imaging techniques 
have a huge impact on the early diagnosis, the design of novel nanocarriers with multi-
modal imaging characteristics is also of great interest and requires the integration in a 
single system of complementary imaging functionalities. The main examples of 
nanovectors which combine MRI with other diagnostic techniques, such as Optical 
Imaging and Positron Emission Tomography (PET), are set out with a particular focus 
on nanoparticle-based multimodal PET/MRI probes
35
. 
  
4.1 Polymer Nanoparticles  
Nanostructured materials have been shown to have some advantages over conventional 
CAs. In this field, Polymeric Nanoparticles (PNPs) have attracted considerable interest 
over the last years due to their properties that can be modulated depending on the 
particular application
36
. Advantages of PNPs as nanovectors include controlled release, 
the ability to combine therapy and imaging (theranostics) in just one particle, 
protection of active molecules and its specific targeting, facilitating improvements in 
the therapeutic index
37
. 
Several hydrophilic polymers, such as Hyaluronic Acid (HA), Chitosan (CS) and 
Dextran are widely used to manufacture PNPs for medical applications. Among them 
HA and its derivatives have been investigated for the development of several carrier 
systems for cancer diagnosis, staging and therapy
38
. HA salts have also been used in   
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combination with CS for drug delivery and diagnostic applications. In this context, 
Chen and coworkers
39
 report a very interesting example of nanotheranostic system in 
which disease diagnosis and therapy are combined. This nanocarrier has a yolk-shell 
structure with a radioluminescent yolk based on Gd2O3:Eu nanospheres, an up 
conversion luminescent in a silica shell, and a coating constituted by HA/CS 
combination for pH-triggered drug release. The deposition of the polymeric 
combination HA/CS is performed in layer-by-layer manner by alternating addition of 
the particles in HA and CS solutions. The resulting system is also able to act as dual 
T1/T2 MRI agents. Mitoxantrone (MTX), selected as anticancer model drug, is loaded 
in the empty area between the core and the shell. The in vitro MTX release from the 
nanocarrier is studied in PBS (pH 7.4) and in acidic conditions (pH 5.0) and, 
interestingly, a marked difference is noted. The drug release occurs with a faster 
kinetic in acidic conditions and it may be favorable in cancer therapy, taking into 
account that in tumors and in endosomes an acidic environment is present. The 
usefulness of the combination HA/CS is also well documented for different bio-
applications
38
. Particularly marked results have been achieved by Courant et al.
40
. Their 
goal is to develop a new and straightforward synthesis of high-relaxivity Gd-NPs for 
MRI applications, with optimized nanoparticle production characteristics, Gd-loading, 
and relaxivity at the same time. They choose to encapsulate a low-risk CA: 
gadolinium-tetraazacyclododecanetetraacetic acid (also known as Gd-DOTA). Because 
of its hydrophilic nature, the encapsulation of Gd-DOTA is made in a hydrophilic 
polymer matrix. For biocompatibility reasons, CH and HA are chosen as polymer 
matrix. A spectacular boost in relaxation rate is found in Gd-DOTA-loaded PNPs. 
Furthermore, recently, Torino et al.
41
 have coupled a flow focused nanoprecipitation to 
an efficient crosslinking reaction based on Divinyl Sulfone (DVS) to entrap the 
relevant clinical gadolinium-diethylenetriaminepentaacetic acid (also known as Gd-
DTPA) in crosslinked Hyaluronic Acid Nanoparticles (cHANPs) able to increase its 
relaxometric properties without the chemical modification of the chelate. Authors 
hypothesize that Gd-chelate modifies the affinity of the polymer solution shifting the 
supersaturation to a low degree and leads to a slow heterogeneous nucleation followed 
- 14 - 
 
by the growth of produced nuclei into large or aggregated particles. These specific 
interactions induce flow perturbation, causing an uncontrolled size variation and 
formation of aggregated morphologies. Subsequently, the macrocyclic molecules have 
been firmly entrapped within the hydrogel matrix, using a crosslinking reaction 
simultaneously occurring with the nanoprecipitation. Investigations related to the 
addition of the DVS in the middle channels or into the side channels have attributed to 
the hydrogel nanoparticles some peculiar properties responsible for the modulation of 
the release behaviour and swelling properties. In vitro MRI results prove that using the 
flexible platform it is possible to take advantages from the strong interference detected 
by the presence of Gd-DTPA producing Gd-entrapped NPs with enhanced MRI 
properties. This observation is crucial to lead potentially to a significant reduction of 
administration dosage on clinical usage of T1 contrast agents and to gain advantages in 
the imaging modalities based on nanotechnologies. Indeed, the nanoparticles (NPs) are 
widely used for the improvement of imaging techniques and all the tunability features 
reported for this system can potentially reduce limitation linked to a fast clearance 
from the bloodstream and low detection due to the dependence on the concentration. 
The proposed approaches aim to overcome some drawbacks of the traditional 
procedures for the production of NPs such as high polydispersity, expensive and time-
consuming purification/recovery steps. Furthermore, results present the effective 
strategy to dose all species and to control property the entrapment of CAs within the 
hydrogel nanostructures that influences MRI performances in the signal intensity and, 
potentially, the tissue specificity. Then, the same authors propose a high versatile 
microfluidic platform to design, in a one-step strategy, PEGylated cHANPs entrapping 
a magnetic resonance imaging CA and a dye for multimodal imaging applications
42
. 
Clinically relevant biomaterials are shaped in the form of spherical NPs through a 
microfluidic flow focusing approach. A comparison between post processing and 
simultaneous PEGylation is reported to evaluate the potentiality of the chemical 
decoration of the cHANPs in microfluidics. An accurate control of the NPs in terms of 
size, PEGylation and loading is obtained. Furthermore, in vitro cell viability is reported 
and their ability to boost the magnetic resonance imaging signal up to 6 times is also 
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confirmed. The proposed microfluidic approach reveals its ability to overcome several 
limitations of the traditional processes and to become an easy-to-use platform for 
imaging applications
42
. All these results drive to the conclusions that the hydration of 
the hydrogel structure can be used to control the relaxometric properties of Gd-DTPA. 
In particular, this concept is explained for the first time by Torino et al.
43
 and called 
Hydrodenticity. The ability to tune the hydrogel structure is proved through a 
microfluidic flow-focusing approach able to produce cHANPs, analyzed regarding the 
crosslink density and mesh size, and connected to the characteristic correlation times of 
the Gd-DTPA. Hydrodenticity explains the boosting (12-times) of the Gd-DTPA 
relaxivity by tuning hydrogel structural parameters, potentially enabling the reduction 
of the administration dosage as approved for clinical use
43, 44
. 
To date, 1H MRI has been widely used in clinical diagnosis, but in recent years, 
researchers have focused on exploring alternative MRI atoms. Among them, the 19F 
atom, as the most promising imaging nucleus, owns several unique features such as 
100% natural isotopic abundance, low background 19F in the human body, relatively 
high sensitivity (83% of protons) and a broad range of chemical shifts. Given that the 
19F element present in the human body exists in bones and teeth, low doses of 
fluorinated agents are required for performing 19F MRI
45
. 
It has been proved that structure of a fluorinated agent is of crucial importance for 
achieving satisfactory MRI performance. Preferably, a 19F MRI agent shall display a 
high fluorine content, high signal-to-noise resonance spectrum, short T1 and long T2. 
To this end, various types of 19F MRI agents have been developed and manufactured 
in the form of delivery vectors for MRI. For example, Wang et al.
46
 prepare 19F 
moiety loaded nanocomposites with an organic fluorescent core via a facile strategy by 
encapsulating organic dyes with oleylamine-functionalized polysuccinimide and 
1H,1H,2H,2H-perfluorodecyltriethoxysilane (PDTES). The aggregation of organic 
fluorescent dyes in the core results in significant fluorescence for optical imaging, 
while the 19F moieties on PDTES allow for simultaneous 19F MRI. Moreover, the 
nanocomposites exhibit high water dispersibility and excellent biocompatibility. These 
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properties make them promising for both cell imaging and in vivo imaging 
applications. 
Among other biomaterials, silica nanostructures have earned a key role in the MRI 
field. Indeed, in contrast to many other nanomaterials, silica NPs do not acquire any 
special property from their sub-micrometer size, except for the corresponding increase 
in surface area. What makes silica NPs fascinating from a nanotechnology point of 
view is their well-defined and tunable structures (i.e., size, morphology and porosity) 
and surface chemistry. By introducing new functional groups via well-established 
siloxane chemistry, it is possible to modify the silica surface to impart new properties 
to the particles, such as diagnostic and therapeutic capabilities. Moreover, silica NPs 
are effectively “transparent” in the sense that they do not absorb light in the near-
infrared (NIR), visible and ultraviolet regions, or interfere with magnetic fields. In 
addition, silica NPs are inexpensive, easy to prepare, relatively chemically inert, 
biocompatible, and water dispersible. A fundamental use of silica particles has been 
reported by Decuzzi et al.
47
. In their work, they demonstrate enhanced efficiency of 
Gd-based CAs (Gd-CAs) by confining them within the nanoporous structure of 
intravascularly-injectable Silicon Micro Particles (SiMPs). Enhancement in efficiency 
is shown for three different Gd-CAs: Magnevist (MAG), a clinically-used Gd
3+
 
polyaminocarboxylate complex, and two carbon nanostructure-based lipophilic agents, 
Gadofullerenes (GFs) and Gadonanotubes (GNTs). The GFs have a single Gd
3+
 ion 
encapsulated by a spherical fullerene cage of ~0.7 nm in diameter. The external 
fullerene cage, which prevents the leakage of the Gd
3+
 ions, can be chemically 
functionalized to provide solubility and biocompatibility. Even after functionalization, 
the GFs exist as aggregates in solution. The GNTs are nanoscale carbon capsules 
(derived from full-length single-walled carbon nanotubes) with a length of 20-80 nm 
and a diameter of about 1.4 nm, which are internally loaded with Gd
3+
 ion clusters. 
Within the GNTs, the Gd
3+
 ions are present in the form of clusters (<10 Gd
3+
 ions per 
cluster), and each GNT contains approximately 50 to 100 Gd
3+
 ions. The Gd
3+
 clusters 
are stable and the Gd
3+
 ions do not leak from the nanocapsules under physiological 
conditions. Because of the hydrophobic nature of their external carbon shealth, the 
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GNTs exist in the form of bundles. In this work, a homogeneous dispersion of GNTs 
(debundled GNTs) is prepared using Na0/THF reduction. 
As assessed in the introduction, multimodal imaging is becoming the new perspective 
into the fields of clinical and preclinical imaging, and nanomedicine represents a valid 
field of application to support its development. Here, it is report a successful example, 
developed by the author of this chapter, to combine boosted MRI with Optical Imaging 
or PET. This is the only case available providing multimodal imaging with improved 
relaxometric properties and without the chemical modification of the chelate. In 
particular, core-shell polymeric NPs are obtained, which can be encapsulated with both 
Gd-DTPA and a dye for Dual Imaging applications through a complex coacervation 
that exploits an innovative double crosslinking to improve the stability of the 
nanostructure overcoming the interference of the Gd-DTPA in the coacervation 
process
48
. Furthermore, the adjustment of the process parameters, the coacervation and 
chemical reaction kinetic promote the interpolation of the hydrophobic core with the 
hydrophilic shell, controlling the water exchange and, consequently, the relaxation rate 
T1, enhancing the MRI signal at reduced concentration compared to the relevant 
clinical CAs. Finally, process conditions able to develop a pH-sensitive behavior of the 
Hybrid Core-Shell (HyCoS) NPs have been identified. 
Further investigations are required to highlight the benefits and the drawbacks of this 
behavior and to consider the system as an effective and safe platform for theranostic 
nanomedicine. Further developments of this project have been the upgrade of the 
designed nanosystem to the trimodal applications and in vivo tests. In particular, a 
study of HyCoS NPs with the Fluorodeoxyglucose (
18
F-FDG) is planned for PET-MRI 
applications
49
. 
 
4.2 Block Copolymers  
 Polymers containing a mixture of repeat units are known as copolymers and they 
occupy an extensive research area and they are well known in, size, and chemical 
composition
50
. For this reason the interest in the synthesis and characterization of   
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copolymers the biomaterials field thanks to their ability to generate nanostructures 
particularly in aqueous solution by varying their architecture is increased enormously 
in the last years thanks also to advances in polymer chemistry. Therefore, the synthetic 
nature of copolymers allows the design of interfaces containing various biochemically 
active functional groups. Among them, Block Copolymers (BCPs) are a specific type 
of copolymer system such that each monomer is homopolymerized to create 
chemically distinct domains. 
A broad range of functional BCPs with tailored properties and organic and also 
inorganic components are now accessible especially for pharmaceutical or diagnostic 
applications
51, 52
. 
An increased number of reports on the synthesis, structures, properties and applications 
of copolymers have been published in the last years
53
. A vast majority of di- and tri-
block copolymers are used for the creation of nanosystems loaded with imaging agents, 
not only to protect these agents from degradation or inactivation in vivo but also to 
optimize dosage and efficacy. These molecules can be physically encapsulated into 
polymer assemblies or covalently conjugated onto polymer chains. Moreover, as 
known, the polymer carriers with surface bioconjugation is the key to prolong the 
bioavailabiliy of the encapsulated active molecules. 
Particularly remarkable are the data reported by Xiao et al.
54
 about a new 
Gadolinium(III)-copolymer (ACL-A2-DOTA-Gd), developed as a potential liver MRI 
contrast agent. ACL-A2-DOTA-Gd consists of a poly (aspartic acid-co-leucine) unit 
bound with Gd-DOTA via the linkage of ethylenediamine. In vitro experiments show 
that new complex is biodegradability, biocompatibility and its relaxivity is 2.4 times 
higher than the clinical Gd-DOTA. In vivo MRI study and biodistribution in rats 
confirm that Gadolinium(III)-copolymers are mainly accumulated in the liver with a 
long time-window. 
Hou et al. 
55
, instead, report a novel approach to synthesize poly(ethylene glycol) 
(PEG)-based Gd-NPs with small size (7 nm) and high relaxivity. They construct a 
pentablock copolymer through two sequential atom transfer radical polymerization 
(ATRP) reactions. The nanostructure consists of a Gd chelates-conjugated block in the 
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center and PEG-terminated segments at both ends. In this way, the interactions of Gd 
chelates with proteins are shielded by the hydrated PEG segments. In vitro and in vivo 
studies demonstrate that the relaxivity is 20 times higher than commercial CA. 
Then, Cao and coworkers
56
 synthesize a new type of triblock polymeric micelle based 
on biocompatible poly(glycerol) (PG) and poly(caprolactone) (PCL) for tumor-targeted 
MRI in vivo. Gadolinium chelates (such as Gd-DOTA) and folic acid (FA) molecules 
are conjugated to PG block through efficient click chemistry reaction and the final 
structure is T-micelle (PCL-PG-PCL-g-DOTA(Gd)+FA) of 250 nm. T-micelles exhibit 
a higher longitudinal relaxivity (r1) and show significant targeting specificity to tumor 
cells. The capability of T-micelle as an MRI CA for contrasting tumor tissue in vivo is 
evaluated in vivo on tumour-bearing mice at different time points. The results indicate 
that FA functionalized T-micelle could provide efficient contrast effect at the tumor 
region through targeting specificity. 
Luo et al.
57
, have successfully synthesized an amphiphilic poly(aminoethyl ethylene 
phosphate)/poly(L-lactide) (PAEEP-PLLA) copolymer by ring-opening polymerization 
reaction, which contains hydrophobic PLLA and hydrophilic PAEEP segments with 
good biocompatibility and biodegradability. Oleylamine-coated Fe3O4 magnetic 
nanoparticles (OAM-MNPs) are encapsulated in the PAEEP-PLLA copolymer 
nanoparticles, while the molecules of lactoferrin (Lf) are conjugated for glioma tumor 
targeting. The results indicate strong, long-lasting, tumor targeting, and contrast-
enhanced MRI ability of Lf-MPAEEP-PLLA-NPs owing to the selectively 
accumulation in brain glioma tissue. 
Another interesting strategy for the development of new contrast reagents is the 
synthesis of amphiphilic Gadolinium(III) complexes that can form spontaneously 
micelles. Jeong and colleagues
58
 synthesize biocompatible amphiphilic derivatives of 
DOTA with hydrophobic alkyl chains, whose gadolinium(III) are incorporated into 
DOTA of micelles via ethylenediamine. To prepare the micelle-formed MRI contrast 
agent with Gd, hydrophilic (mPEG) and hydrophobic moieties (hexadecylamine) are 
conjugated with the PHEA backbone. PEG chains, being exposed to the external 
aqueous phase. The final structure (PHEA-mPEG-C16-ED-DOTA-Gd) has an average 
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diameter of 180 nm and can be used for the detection of liver lesion. In vitro 
experiments show that this nanovector give better imaging contrast than commercial 
contrast agent at low concentration of Gadolinium. Therefore, when solution of PHEA-
mPEG-C16-ED-DOTA-Gd is intravenously injected into a rabbit, the T1-weighted 
image of the liver in an animal model shows prolonged intravascular duration time of 
about 30 min. 
With the rapid development of polymer synthetic and nano-techniques, stimuli-
responsive block copolymers and corresponding assemblies are created one after 
another and used for targeted delivery of drugs and imaging/contrast agents to tumor 
sites. These vehicles are able to react to internal environmental changes, such as 
temperature, ionic strength, light, pH level, pressure, and so on or external stimuli 
(light and electromagnetic field) exhibiting reversible or irreversible changes in 
chemical structures and physical properties
59
. 
In particular, the measurement of pH in vivo has received considerable attention 
because, in presence of solid tumors, it provides the potential not only for early 
detection and diagnosis of tumors but also for monitoring the efficacy of the treatment 
plan used to combat the disease
60
. The non-invasive measurement of pH is based on 
MRI. Gao and coworkers
61
 are one of the first groups to prepare a stimuli-responsive 
BCPs by encapsulation of iron oxide NPs in a pH-responsive diblock copolymer, 
consisting of poly(ethylene oxide) (PEO) as the hydrophilic, biocompatible segment 
and a poly(β-amino ester) (PAE) as the pH-sensitive segment. When the pH is low 
(<7.0), the transverse relaxivity (r2) of the imaging agent increases due to the release 
of the iron oxide nanoparticles from the core of the micelles. Subsequently, Okada et 
al.
62
, develop a different approach to prepare a pH-responsive system by attaching Gd-
chelates to a poly(methacrylic acid) (PMAA). MRI in vitro studies indicate that the 
relaxivity of the contrast agent increases of two times when the environmental pH is 
acid. Also Zhu et al.
63
. design a pH-responsive MRI CA that demonstrates significant 
changes in term of relaxivity upon changes in the environmental pH at physiological 
relevant values. Recently, to enhance the stability of polymeric micelles, Hu et al.
64
 
report the fabrication of cross-linked micellar structure, which covalently labelled with 
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DOTA(Gd) and green-emitting fluorophores within pH-responsive cores, serving as a 
dual-modality MR/fluorescence imaging agents. The acidic pH-triggered turn-on and 
enhancement of signal intensities for both imaging modalities are declared. Compared 
with non-cross-linked diblock precursor, this system shows better MR and 
fluorescence imaging performance due to structural stability. Subsequently, the same 
group develops a novel theranostic polyprodrug platform with synergistic 
imaging/chemotherapy capability consisting of hyperbranched cores conjugated with 
reduction-activatable prodrugs (an anticancer agent) and MRI CA (Gd complex), and 
hydrophilic coronas functionalized with guanidine residues
65
. The hyperbranched cores 
avoid the potential interactions between anticancer agent and blood components and 
serve as the embedding matrix for MR contrast agents to weaken MR background 
signals. Upon cellular internalization, the synergistic turn-on of therapeutic potency 
and enhanced diagnostic imaging in response to tumor milieu are achieved. 
Mouffouk et al.
66
, for example, report the development of a smart CA composed of pH-
sensitive micelles containing a hydrophobic Gd(III) complex with the aim of 
specifically detecting cancer by MRI. This vector (35–40 nm) consists of pH-sensitive 
polymeric micelles formed by self-assembly of a diblock copolymer 
poly(ethyleneglycol-b-trimethylsilyl methacrylate) (PEG-b-PTMSMA), loaded with 
the hydrophobic complex tetraaquodichloro(4,4’-di-t-butyl-2,2’-bipyridine) 
Gadolinium(III) chloride (tBuBipyGd) and decorated with a specific monoclonal 
antibody (mAb) against the human MUC1 protein, which is more expressed in many 
epithelial cancers and a specific targeting vector in preclinical and clinical trials. This 
system is able to amplify the MRI signal chemically and at the same time has the 
ability to remain silent during circulation; in fact, the CA remained in the “off state,” 
being activated only upon micelle disruption in an acidic medium represented by 
tumour microenvironment. In fact, the extracellular pH of most tumor tissues is weakly 
acidic (pH 6.5), which is lower than that of normal tissues (pH 7.2) and this 
discrepancy is usually used as the trigger factor. Finally, the conjugation of a specific 
biomolecule to smart agents increases significantly their affinity toward cancer cells. 
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Other stimuli-responsive BCPs are extensively studied. Tsai et al.
67
, for example, 
develop a core-shell structure composed by poly(HEMA-co-histidine)-g-PLA and 
diblock copolymer PEG–PLA with functional moiety. The inner core of poly(HEMA-
co-histidine)-g-PLA exhibits pH stimulate to enable intracellular drug delivery, while 
the outer shell PEG-b-PLA with functional moiety Cy5.5 for biodistribution diagnosis 
and folate for cancer specific targeting. The nanospheres has an average diameter of 
200 nm. From drug release study, a change in pH destroy the inner core to lead a 
significant drug release from mixed micelles. Cellular uptake of folate–micelles is 
found to be higher than that of non-folate–micelles. In vivo study reveal that specific 
targeting of folate–micelles exhibit cancer targeting and efficiency expression on tumor 
growth, indicating that multifunctional micelles prepared from poly(HEA-co-
histidine)-g-PLA and folate–PEG–PLA have great potential in cancer chemotherapy 
and diagnosis. 
Concomitantly, additional and promising technologies in nanomedicine are currently 
under investigation such as multimodal imaging, which combines two or more 
diagnostic strategies into one procedure and nanotheranostics, which integrates both 
therapeutic and diagnostic capabilities into one single nanoplatform. 
Locatelli et al.
68
, for example, report a nanocarrier system for dual PET/MRI imaging. 
In this case hydrophilic superparamagnetic maghemite NPs are synthesized and coated 
with a lipophilic organic ligand and the entrapped into polymeric NPs made of 
biodegradable poly(D,L-lactide-co-glycolide)-block-poly(ethylene glycol) copolymer 
(PLGA-b-PEG-COOH). Moreover, the surface of NPs show active sites (COOH) that 
allow a modification with 2,2’-(7-(4-((2-aminoethyl) amino)-1-carboxy-4-oxobutyl)-
1,4,7-triazonane-1,4-diyl) diacetic acid (NODA) to chelate 
68
Ga for PET imaging. 
Zhang and coworker
69
, instead, realize a copolymer-based single-photon emission 
computed tomography/magnetic resonance (SPECT/MR) dual-modality imaging agent 
that can be labeled with technetium-99m (
99
mTc) and Gd simultaneously. The 
copolymer P(VLA-co-VNI-co-V2DTPA) (pVLND2) is synthesized by radical 
copolymerization reaction and based on asialoglycoprotein receptor (ASGPR) targeting 
agent for hepatic tissue. 
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An example of theranostic polymer platform is developed by Porsch et al.
70
. In this 
work, they report the use of natural isotope 
19
F as an efficient alternative to the 
conventional imaging costrast agents, because this nucleus is not intrinsic to the body, 
thus enabling MRI images with great spatial selectivity against a zero background and 
synthesize fluorinated NPs loaded with doxorubicin (Dox). The NPs are formed by 
self-assembly of amphiphilic BCPs with ﬂuorinated elements incorporated in the 
hydrophilic corona and anticancer drug in the hydrophobic core. Experimental data 
show that the nanovector has a controllable drug release kinetics, are detectable by 
19
F-
MRIand toxic for breast cancer cells. 
Recently, Koziolova and colleagues
71
 evaluate the influence of molecular weight and 
dispersity of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates with 
Dox on their biodistribution is studied using two complementary imaging methods 
PET and Fluorescence Imaging (FI). The HPMA copolymers are synthesized by RAFT 
polymerization and functionalized with a chelator for further radiolabelling with 
Zirconium-89(
89
Zr; t1/2 = 78.4 h) prior to in vivo and ex vivo studies. PET/Optical 
Imaging studies indicate that dispersity and molecular weight of the HPMA polymer 
carriers have a significant influence on the in vivo fate of the polymer conjugates and 
thanks to presence of anticancer drug bound show higher cytotoxicity and cellular 
uptake in vitro. 
 
4.3 Liposomes  
 Liposomes are structures composed of hydrophobic head groups and hydrophilic tail 
groups. They can be prepared by adding lipids in organic solution, which is slowly 
evaporated to produce a thin film. The film is then hydrated with a desired aqueous 
buffer and sonicated. Liposomes are generally nano-scaled structures and can be 
further size refined by passage through physical membrane pores of known size 
(extrusion). Liposomes are typically characterised by their size, shape and lamellarity. 
They may be composed of a single bilayer (unilamellar), a few bilayers (oligolamellar), 
or multiple bilayers (multilamellar). Due to their aqueous cavity and “tunable” bilayer,   
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liposomes have traditionally been used as drug delivery vehicles, encapsulating water-
soluble drugs within the aqueous cavity in order to improve drug pharmacokinetics 
72
.  
Zou et al.
73
  for example, report an amphiphilic MRI-traceable liposome NPs 
encapsulating Gd-DOTA for in vivo inner ear visualization through MRI. They design 
these multifunctional NPs through the film hydration method that allows the 
encapsulation of Gd-DOTA inside the hydrophilic core of the NPs. They observe 
acceptable relaxivity values allowing visible signal characteristics for MRI. In vivo 
studies demonstrate that these systems are efficiently taken up by the inner ear after 
both transtympanic and intracochlear injection. The latter shows better NPs distribution 
throughout the inner ear, including the cochlea and vestibule, and induced stronger 
MRI signals on T1-weighted images. 
Bui et al.
74
 produce lipid NPs containing phospholipids that express Gd-chelate or 
DTPA by incorporating DTPA-PE into the lipid core of the NPs and then adding Gd
3+
 
to preformed NPs (for binding to Gd
3+
 as Gd-DTPA-PE chelate). They also add 10-
mole percentage of lipid conjugated to mPEG-PE to lipid nanoparticles in order to 
increase the bound water on the lipid nanoparticle surface, thereby increasing the MRI 
contrast. In this case, the following nanoparticle system shows an higher longitudinal 
relaxivity (33-fold) than the current FDA approved Gd-chelated CAs. In addition, 
intravenous administration of these Gd-LNP at only 3% of the recommended clinical 
Gd dose produce MRI signal-to-noise ratios of greater than 300 times in all 
vasculatures. 
Kamaly and collegues
72
 synthesize a bimodal imaging liposome for cell labeling and 
tumour imaging. The lipid molecules are able to bear both ﬂuorophore and CA on the 
same structure, thereby representing a useful probe for both MRI and ﬂuorescence 
microscopy utility. Very briefly, they conjugate a rhodamine moiety onto a DOTA-
bearing C-18 dialkyl lipid and complex Gd into the molecule to obtain the bimodal 
lipid Gd DOTA Rhoda DSA 1. The lipid is used to label IGROV-1 human ovarian 
carcinoma cells and to image xenograft tumours in mice. The new paramagnetic and 
ﬂuorescent lipid proved to be a valuable probe to obtain anatomical information, 
through MRI, and liposome biodistribution, through ex vivo ﬂuorescence microscopy. 
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Kono et al.
75
 synthesize multi-functional pegylated liposomes having both highly 
thermosensitive polymers and newly synthesized Gd-chelate-attached dendron lipid  
(G3-DL-DOTA-Gd) with a compact conformation. The multifunctional liposomes 
show temperature-responsive drug release and MR imaging functions. In particular, 
authors load liposomes with Dox and tested the stability of the nanostructures, showing 
that liposomes are able to retain Dox below physiological temperature but release it 
immediately above 40°C. As far as the MRI properties, the developed liposomes 
exhibit the ability to shorten the longitudinal relaxation time with a relaxivity (5.5 mM
-
1
s
-1
) higher than that of free Gd-DOTA (4.6 mM
-1
s
-1
).  
In addition, Na and co-worker
76
  report dual functional liposomes co-encapsulating 
Dox and Gd as therapeutic and diagnostic carriers. They measure MR relaxivity and 
cellular uptake showing that the liposomes can entrap 3.6 mM of Dox and 1.9 mM of 
Gd. Although the low relaxivity (5.5 mM
-1
s
-1
) compared to that of MRbester
®
 due to 
limited water diffusion across the liposome membrane, the surface charge induced 
good cellular uptake, allowing a higher accumulation of Gd into cells than MRbester
®
. 
Additionally, Dox is more easily internalized to the nucleus compared to Doxil
®
. 
Li et al.
77
, instead, prepare fluorescent and paramagnetic liposomes for early tumor 
diagnosis by incorporating a RGD-coupled-lipopeptide, synthesized using a cyclic 
RGD peptide headgroup coupled to palmitic acid anchors via a KGG tripeptide spacer, 
into lipid bilayers. As far as the paramagnetic liposomes, they adopted the thin film 
hydration method and hydrated the lipid film with commercial Gd-DTPA as MRI 
contrast agent. In vivo MRI scanning demonstrate that the signal enhancement in tumor 
after injection of RGD-targeted liposomes is significantly higher than non-targeted 
liposomes and pure Gd-DTPA. In addition, biodistribution study also show specific 
tumor targeting of RGD-targeted paramagnetic liposomes in vivo, proving them an 
effective means for noninvasive diagnosis of early tumor. 
Liao et al.
78
 design a core-shell NPs system composed of a PLGA core and a 
paramagnetic liposome shell for simultaneous MRI and targeted therapeutics. They 
encapsulate Dox within biocompatible and FDA-approved PLGA NPs, and DTPA-Gd 
is conjugated to the amphiphilic octadecyl-quaternized lysine-modified chitosan 
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(OQLCS). The paramagnetic liposome shell is based on Gd-DTPA-conjugated OQLCS 
(Gd-DTPA-OQLCS), folate-conjugated OQLCS (FA-OQLCS), and PEGylated 
OQLCS (PEG-OQLCS). Briefly, the carboxyl groups of DTPA used as a chelating 
agent are combined with the amino groups of OQLCS. Then Gd is incorporated into 
the complex. As a result, the NPs show paramagnetic properties with an approximately 
3-fold enhancement in the longitudinal relaxivity (r1 = 14.381 mM−1s−1) compared to 
the commercial Gd-DTPA complex and exceptional antitumor effects without systemic 
toxicity. 
Another remarkable example as reported by Gianolio et al.
79
. They prepare pH-
responsive Gd-DO3Asa-loaded liposomes which maintain the pH responsiveness of 
the unbound paramagnetic complex, and their relaxivities are markedly affected by the 
magnetic field strength, exhibiting a steep change in the relaxivity in the pH range 5-
7.5. Moreover, they provide a ratiometric method for measurement of the pH based on 
a comparison of the relaxation effects at different magnetic fields, offering an 
alternative tool for accessing measurement of the pH without prior knowledge of the 
concentration of the paramagnetic agent. 
Subsequently, Hossann et al.
80
 investigate formulations of 6 clinically approved CAs 
encapsulated into thermosensitive liposomes (TLs): 
 
(1) Gd-DTPA (Magnograf®) from Marotrast GmbH, Jena, Germany; 
(2) Gd-BOPTA (Multihance®) from Bracco Imaging Deutschland GmbH 
(Konstanz, Germany); 
(3) Gd-DOTA (Dotarem®) from Guerbet GmbH (Sulzbach/Taunus, Germany); 
(4) Gd-BT-DO3A (Gadovist™) from Bayer Vital GmbH (Leverkusen, Germany); 
(5) Gd-DTPA-BMA (Omniscan™) from GE Healthcare Buchler GmbH & Co. 
KG (Braunschweig, Germany); 
(6) Gd-HP-DO3A (Prohance®) from Bracco Imaging Deutschland GmbH 
(Konstanz, Germany). 
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They observe that Omniscan™ and Prohance® are the most promising candidates to be 
encapsulated into DPPG2-TSL. In particular, Prohance
®
 allows the highest loading 
capability (256 mM) due to the lowest osmolality and yielded the highest relaxivity. 
Omniscan™ is the only formulation that could be stored at 4°C for weeks. The other 
CAs induce phospholipid hydrolysis, which results in unwanted CA leakage, and 
therefore reduce the shelf life of TSL. Nevertheless, Omniscan™ is associated with 
nephrogenic systemic fibrosis (NSF)
81
. 
The Human Serum Albumin (HSA) and Immunglobulin G (IgG) contribute to the 
increase of MRI signal at 30°C by increasing Pd. A high concentration of encapsulated 
CA is a prerequisite to achieve a sufficiently high Δr1 during heat triggered CA release 
combined with a low r1 at 37°C. Hence, the optimal CA is characterized by a non-ionic 
structure and a low contribution to osmolality. 
Cheng et al.
82
, instead, encapsulate Gd within a nanometer-sized stabilized porous 
liposome in order to increase the Gd relaxivity thanks to the porous structure, enabling 
a fast water exchange rate. A further increase in relaxivity (up to 9.9 mM
-1
s
-1
) is 
achieved by attaching large molecular weight dextran to the Gd moiety (Gd-DOTA) 
prior to encapsulation. 
Others authors report further interesting strategies for the development of new 
liposome-complexes. Park and coworker
83
 develop nanohybrid liposomes coated with 
amphiphilic hyaluronic acid-ceramide for targeted delivery of anticancer drug and in 
vivo cancer imaging. Dox, an anticancer drug, and Magnevist, a Gd-based CA for MRI, 
are loaded into this nanohybrid liposomal formulation. They find that in vitro release 
and in vivo clearance of Dox as well as cellular uptake from the nanohybrid liposome 
is enhanced than that from conventional liposome, thanks to the prolonged circulation 
of the nanohybrid liposome in the blood stream and to the HA–CD44 receptor 
interactions. 
Another example is reported by Smith and Kong
84
. In this case, it is evaluated the 
stability of liposomes with Gd-loaded in presence of serum. The authors assemble 
crosslinkable liposomes composed of diyne-containing lipids, conjugate the liposome 
surface to DTPA-chitosan-g-C18 and then crosslink the liposome via UV irradiation. 
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The particles are mixed with Gd to enhance the quality of MRI contrast. They 
demonstrate that the crosslinking strategy after the adsorption of the polymer fastener 
allows stabilizing the thermodynamically favorable association between liposome and 
DTPA-chitosan-g-C18. In the end, they observe that CS-coated crosslinked liposomes 
are more effective than non-crosslinked liposomes in terms of stability, showing 
reduced liposome degradation and chitosan desorption. 
Concomitant, Gu et al.
85
 develop novel Gd-loaded liposomes guided by GBI-10 
aptamer for enhanced tumor MRI. They conjugate GBI-10, as targeting ligand, onto 
the liposome surface and the so obtained system shows an accumulation of Gd at the 
periphery of C6 glioma cells, where the targeting extracellular matrix protein tenascin-
C is overexpressed. This novel design strategy, obtained by simply replacing the 
aptamers with other kinds of aptamers, can be applied to a variety of target cells with 
high efficiency and specificity. 
Silva et al.
86
 synthesize and incorporate complexes of Gd with aliphatic chain ligands 
of N-alkyl-N-methylglucamine series into liposomes in order to enhance MRI contrast. 
The presence of two aliphatic chains is conceived to reduce the local rotational motion 
of the Gd-complexes after incorporation in the liposomal bilayer. They show that the 
incorporation into liposomes is accompanied by an increase of the vesicle zeta 
potential and in relaxation effectiveness (r1 up to 15 mM
-1
s
-1
) compared to commercial 
Gd-DTPA, presumably because of the slower molecular rotation due to the elevated 
molecular weight and incorporation in liposomes. 
Xiao et al.
87
  report liposomes loaded with Sorafenib (SF) and commercial Gd-based 
CA (Gd-DTPA) for theranostic applications. Thin film hydration method is used to 
prepare liposomes exhibiting spherical shapes or ellipsoidal shapes, uniform particle 
size distribution (around 180 nm), negative zeta potential, high encapsulation 
efﬁciency and drug loading. As far as the longitudinal relaxivity, they achieve a value 
of 3.2 mM
-1
s
-1
, slightly lower than the commercial CA (4.5 mM
-1
s
-1
) and the MRI test 
show longer imaging time and higher signal enhancement at the tumor tissue. 
Furthermore, they demonstrate in vivo antitumor efﬁcacy of the developed SF/Gd-
liposomes on hepatocellular carcinoma (HCC) in mice. To sum up, the authors show 
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that SF/Gd liposomes could be promising nano-carriers for MRI-guided in vivo 
visualization of the delivery and HCC treatment. 
In the end, Tian et al. synthesize Gd-DTPA-loaded mannosylated liposomes (M-Gd-
NL) and test their ability to target macrophages in Acute Pancreatitis (AP) and 
discriminate between mild and severe AP. Lipid film-based method is used to 
synthesize DSPE-PEG2000-Man liposomes encapsulating DPPE-DTPA-Gd, with size 
around 100 nm. In vitro tests show efficient bind and readily release of Gd-DTPA into 
macrophages, resulting in enhanced MRI ability. Indeed, M-Gd-NL show a 
longitudinal relaxivity 1.8-1.9 higher than Gd-DTPA, as a consequence of the 
embedding of DPPE-DTPA-Gd into the bilayer of liposomes, which slowed down the 
tumbling motion of Gd complexes. As far as the safety profile, M-Gd-NL do not show 
any severe organ toxicity in rats, thus proving to be promising nanocarriers for clinical 
use and for the early detection of AP. 
 
5. Aim of work 
The large variety of systems now available in the nanometric scale represents a clear 
advantage in diagnostic and therapy of some of the most challenging human 
pathologies. In this context, the following thesis project has been focused on the design 
and synthesis of new CAs for MRI applications.                                                       
Initially, the basic principles ruling biopolymer-CA interactions are clearly highlighted 
in the perspective of their influence on the relaxometric properties of the CA by 
adopting a multidisciplinary experimental approach. HA
88
 is used as a model polymer 
because of its biocompatibility and high hydrophilicity. 
In this theoretical framework, the peculiar effect of Hydrodenticity on the polymer 
conformation and the formation of the stable water compartments responsible for the 
enhancement of the MRI signal is introduced and discussed. Then, the acquired 
knowledge about polymer-CA systems to apply the concept of Hydrodenticity to the 
design of Gd-based polymer NPs with enhanced relaxometric properties. Thus, the 
development of the nanomaterial drug carriers, based on biopolymer nanoparticles,   
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physically and chemically characterizations of interactions between hydrophilic 
biopolymers and Gd-based CAs, and possible medical applications (lymphoma and 
atherosclerosis diseases) are reported here.  
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CHAPTER I  
Impact of water dynamics on 
relaxometric properties of Gd-DTPA. 
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1. Introduction 
Recently, rational design of a new class of CAs, based on biopolymers (hydrogels), 
have received considerable attention in MRI diagnostic field and several strategies 
have been adopted to improve relaxivity without chemical modification of the 
commercial CAs. As reported by Port et al. 
89, rigidiﬁcation of Gd-based CAs would be 
favourable to an increase in the relaxivity of the metal chelate since the presence of the 
ligand around the Gd ion induces a shortening of the residence lifetime of the inner-
sphere water molecules (τM) 
89-91
. In addition, they hypothesized that the presence of a 
rigid coordination cage of a chelate should limit its intramolecular conformational 
motions, which distorts the ligand ﬁeld at the metal centre due to solvent molecules 
collisions, thus influencing the electronic relaxation times (τS1 and τS2) 
89
. To assess the 
rigidification strategy, Port synthetized a constrained derivative of Gd-PCTA12, Gd-
cyclo-PCTA12, in which one ethylene bridge connecting two nitrogen atoms of the 
triamine block is replaced by a cyclohexylene bridge, and the impact of rigidification 
was studied by comparing the physicochemical and relaxometric properties of both 
gadolinium MRI contrast agents, Gd-PCTA12 and Gd-cyclo-PCTA12. 
Other experimental approaches studied by Decuzzi et al. 
47, 92, 93
 proved that 
geometrical confinement could limit the mobility of water molecules and thereby 
enhance the relaxation response of Gd-based CAs without its chemical modification. In 
particular, they observed that nanometric pores of silica microparticles increase the 
rotational correlation time (τR) of Gd-DTPA (inner-sphere effect), which cannot tumble 
freely being adsorbed on the walls of the 100 nm pores. At the same time, it also 
increases the diffusion correlation time (τD) for water molecules (outer-sphere effect), 
which are geometrically confined and forced to interact longer with Gd-DTPA 
adsorbed to the inner pore surface 
93
. Through the confinement strategy, a poor 
increment of the relaxivity can be obtained without modifying the chemical structure of 
the CA. 
As advancement of the geometrical confinement, in some more recent works, Courant 
et al. 
40
 and Callewaert et al. 
94
, showed that biocompatible hydrophilic hydrogels can 
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be exploited to produce high water content nanoparticles (NPs) encapsulating the metal 
chelate. Inside the hydrogel, which creates a favourable aqueous environment for Gd-
based CAs 
88, 95-97
, the rotational motion of the encapsulated CA (Gd-DOTP, Gd-
DOTA and Gd-DTPA) is restricted and its magnetic properties are amplified. 
In our recently published works 
98, 99
, we have initially analysed the impact that 
hydrophilic biopolymer networks have on the relaxivity of Gd-based CAs and 
explained the role of the water in the interaction between polymers and metal chelates. 
This concept, called “Hydrodenticity”, has been the subject of further investigations as 
reported by Russo et al. 
43
. In a still previous work published by Russo and co-worker 
41
, crosslinked Hyaluronic Acid NanoParticles (cHANPs) containing a Gd chelate (Gd-
DTPA), are synthesized through a microfluidic platform that allows a high degree of 
control over particle synthesis, enabling the production of monodisperse particles as 
small as 35 nm for MRI applications. The relaxivity (r1) achieved with the cHANPs is 
12-times higher than Gd-DTPA. Within cHANPs, the properties of Hydrodenticity can 
be modulated to obtain desired mesh size, crosslink density, hydrophilicity and loading 
capability, as reported by Russo et al. 
42, 43
. Moreover, they proved that an increase of 
the crosslinking degree of biopolymer can induce the enhancement of relaxivity by 
restricting molecular tumbling while maintaining the switching property 
100
 and 
allowing easy access of water throughout the structure, which is a key feature in MRI 
CAs. The possibility to adopt a unique platform to tune the hydrogel structural 
parameters and, consequently, increase the relaxivity of a metal chelate without any 
chemical modification, could have a great impact on the clinical outcome. In fact, 
thanks to their improved relaxometric properties, cHANPs could ensure a brighter 
contrast with a lower amount of metal chelate, thus enabling the potential reduction of 
the administration dosage as approved for clinical use. 
In a further work 
101
, we reported an efficient way to produce Hybrid Core-Shell 
(HyCoS) NPs composed of a Chitosan core and a shell of HA with improved 
relaxometric properties (up to 5-times than the commercial CA). Subsequently, the 
same nanosystem is used to develop a new nanoprobe for simultaneous Positron 
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Emission Tomography (PET)/MRI acquisitions as reported in our more recent 
publication 
102
. 
Based on the above reported works, it has been finally demonstrated that the polymer 
architecture affects some characteristic parameters of the metal chelate and tunes its 
relaxometric properties 
40, 43, 92, 103-105
. Moreover, it is clear that crosslinked biopolymers 
can have a significant role to overcome the limitations of clinically relevant CAs 
without their chemical modification and as a compound in the design of advanced 
nanostructures with improved safety profile and switchable relaxometric properties. 
Indeed, it is known that the functional properties as well as the swelling behaviour of 
hydrogels are influenced by the hydration degree, which can be likely modulated by 
changing the chemical composition of the system 
106-112
. 
Here, we aim to highlight the basic principles ruling biopolymer-CA interactions in the 
perspective of their influence on the relaxometric properties of the CA by adopting a 
multidisciplinary experimental approach. HA 
88
 is used as a model polymer because of 
its biocompatibility and high hydrophilicity. We characterize, physically and 
chemically, the interactions between hydrophilic biopolymers and Gd-based CAs. In 
this theoretical framework, the peculiar effect of Hydrodenticity on the polymer 
conformation and the formation of the stable water compartments responsible for the 
enhancement of the MRI signal is introduced and discussed.  
 
2. Experimental Section 
2.1 Materials 
All chemicals used are of analytical reagent grade quality and are employed as 
received. Divinyl sulfone (DVS, 118.15 Da), Diethylenetriaminepentaacetic acid 
gadolinium(III) dihydrogen salt hydrate (Gd-DTPA, 547.57 Da) and Sodium hydroxide 
pellets (NaOH).                                Sodium Hyaluronate, with an average molecular 
weight of 850 kDa (purity 99%; Hyasis® 850P) and 42 kDa, is respectively supplied 
by Novozymes Biopharma and Bohus Biotech (Sweden) as dry powder and used 
without purification.  
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Magnevist
® 
(Bracco Imaging, Italy), a contrast agent commercially available, is used in 
this study. The water is purified by distillation, deionization, and reserve osmosis 
(Milli-Q Plus) and systematically used for sample preparation, purification and 
analysis. All experiments are repeated in triplicate and conducted at room temperature, 
25°C. 
2.2 Isothermal Titration Calorimetry  
Titration experiments are performed by using a Nano ITC Low Volume calorimeter 
(TA Instruments). CA and polymer are prepared in double-distilled filtered water 
without any additives. The sample cell (700 µL) and the syringe (50 µL) are filled with 
aqueous solutions of HA and Gd-DTPA respectively. Syringe Gd-DTPA concentration 
is fixed at 1.5 mM, while different HA concentrations in the sample cell are tested, 
ranging from 0.3 to 0.7% w/v. The measurements are performed at 25 °C and at fixed 
stirring rate of 200 rpm. Fifty Injections, each of 1 μL of Gd-DTPA, are delivered in 
intervals of 500 s. The concentration of polymer is expressed as the mass of the repeat 
unit (unit mol/L).          Data analysis and processing to provide ITC and enthalpy 
change (ΔH) profiles is carried out using the NanoAnalyze (TA instruments) and the 
OriginPro software. 
2.3 NMR 
1
H NMR spectra are recorded at 25 °C with Varian Agilent NMR spectrometer 
operating at 600 MHz to observe chemical interactions between polymer and chelating 
agent (DTPA). The NMR samples consisted of water solution of HA-DTPA at 
different molar ratios (HA/DTPA ranging from 0 to 0.5), with 10% v/v D2O. 
Diffusion-ordered NMR Spectroscopy (DOSY) are also performed and the z-gradient 
strengths (Gz) is varied in 20 steps from 500 to 32500 G/cm (maximum strength). The 
gradient pulse duration (δ) and the diffusion delay (Δ) are kept costant, 2 ms for δ and 
ranging from 7 to 1000 ms for Δ. After Fourier transformation and baseline correction, 
DOSY spectra are processed and analysed using Varian software VNMRJ (Varian by 
Agilent Technologies, Italy) in order to obtain the values of water self-diffusion 
coefficient.  
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2.4 Differential Scanning Calorimetry 
For all measurements the HA/water solution (Mw = 42 kDa) is used. The aqueous 
solutions are prepared in a concentration range of polymer 0.3–0.7% w/v. Next, Gd-
DTPA is added as CA at different molar ratio HA/Gd-DTPA (from 1:0.25 to 1:3) and 
stirred for 12 h. The hydrated polymer samples, with and without CA, are sealed at 
room temperature in a Tzero hermetic pans prior to analysis. DSC measurements are 
performed in a TA Instruments’ Q20TM calorimeter on samples between 5 and 10 mg. 
The samples are cooled down from 25°C to -50°C followed by heating scan up to 
25°C. The same heating and cooling rate are 10°C/min for all runs. Samples are tested 
in triplicate to ensure reproducibility. For DSC and ITC measurements, we used low 
molecular weight HA (42 kDa) to highlight better the energetic contributions of 
different components without exceeding the maximum scale of the instruments. 
2.5 Time-Domain Relaxometry  
The spin-lattice relaxation times (T1) are measured in a Bruker Minispec (mq 60) 
bench-top relaxometer operating at 60 MHz for protons (magnetic ﬁeld strength: 1.41 
T). Measurements are taken at 37°C, and before NMR measurements, the tube is 
placed into the NMR probe for about 15 min for thermal equilibration. Experiments are 
made using water solutions of Gd-DTPA (from 0 to 0.1 mM) and HA (0.3, 0.5 and 
0.7% w/v) crosslinked with DVS (DVS/HA weight percentage ratio equal to 1:8). T1 
values are determined by both saturation (SR) and inversion recovery (IR) pulse 
sequences. The relaxation recovery curves are ﬁtted using a multi-exponential model. 
Relaxivities, r1, are calculated from the slope of the regression line of 1/T1 [s
-1
] versus 
concentration [mM] with a least-squares method.  
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3. Results and Discussion 
3.1 Diffusive mixing time in Hydrodynamic Flow Focusing approach 
The polymer conformation can be modified by the affinity with the solvent solution 
113, 
114
. Furthermore, the addition of a solute can still induce a change in the polymer 
conformation. In our previous work, we proved that the  relaxivity of CAs can be 
modulated combining them with macromolecules or polymers 
98
. Therefore, the 
understanding of the interaction between polymers and CAs in aqueous solution could 
be critical to tune the relaxometric properties of CAs. We aim to show how the 
presence of the Gd-DTPA in the aqueous solution can influence the behaviour of the 
polymer matrix and, on the other side, how these adjustments of the polymer 
conformation can govern the characteristic correlation times of the Gd-DTPA 
41, 43, 98
. 
To investigate thermodynamic interactions between polymer and contrast agent, HA 
and Gd-DTPA respectively, are selected to be tested by Isothermal Titration 
Calorimetry (ITC). We aim to take advantage of the molecular interactions that are 
accompanied by some level of heat exchange between the interacting system and its 
surrounding medium; indeed, these interactions can be evaluated, at constant 
temperature, through the ITC. Basic principles of this technique have been widely 
discussed elsewhere 
115, 116
 
Titration experiments are conducted injecting a solution of Gd-DTPA in the ITC cell 
containing the polymer solution. Different HA concentrations, ranging from 0.3 to 
0.7% w/v, are tested and more representative results are reported in Figure 1 (peaks 
above the baseline represent exothermic phenomena while peaks below the baseline 
represent endothermic phenomena). It is clear that significant enthalpy variations are 
obtained in the titration experiments (Figure 1A-C) and can be associated with the 
water-mediated interaction between the Gd-chelate and the polymer, which induces 
changes in polymer chains’ conformation. Since Figure 1A-C show ITC thermograms 
varying the HA concentration in the sample cell, a wide range of Gd-DTPA/HA molar 
ratios is examined and the relative energetic contribution and enthalpy values are 
calculated by integrating peaks of the experimental curves and are reported in Figure 
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1D. Simple dilution of Gd-DTPA in water (Figure 1 bis) exhibits only small constant 
exothermic peaks over the whole experiment. 
In Figure 1, it is worth noting that the energetic contribution decreases as the Gd-
DTPA/HA molar ratio increases; thus, the higher is the concentration of HA in the 
sample cell, the higher is the Gd-DTPA concentration needed to observe endothermic 
peaks. It can also be observed that the endothermic contribution exceeds the 
exothermic one at the recurrent Gd-DTPA/HA ratio approximatively equal to 0.5 
through all the experiments at different HA concentrations in the sample cell. It means 
that a specific energetic contribution is needed to induce the adjustment of the polymer 
conformation. Then, when the Gd-DTPA/HA molar ratio equals 0.5, the endothermic 
peaks start slightly increasing until reaching a plateau, which corresponds to the 
thermodynamic equilibrium established within the ternary system (polymer-CA-water). 
The measured energetic variation reflects the conformational changes of polymer 
chains due to the presence of the CA in solution and leads to the formation of stable 
sub-domains in which a balanced exchange of water molecules occurs between the 
polymer, the CA and the bulk. 
The attainment of this thermodynamic equilibrium derives from a water-mediated 
interaction occurring between HA and Gd-DTPA. As both hydrophilic components, 
HA and Gd-DTPA interact with the water by forming hydrogen bonds and by 
coordinating water molecules. This competitive behaviour generates a measurable heat 
that reflects the change in polymer chains conformation and the exchange of bound 
water molecules with the bulk, thereby, bringing the system to a more stable 
configuration. In our previous paper 
43
, we preliminary showed how this equilibrium is 
able to affect the relaxometric properties of the system, as an effect of the new concept 
of Hydrodenticity, which will be further explained in the following paragraphs.  
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Figure 1. Titration curves of Gd-DTPA into aqueous polymer 
solutions at 25 °C. Calorimetric traces (heat flow against time) for 
(a) 0.3% w/v HA, (b) 0.5% w/v HA and (c) 0.7% w/v HA. In (d) it 
is reported the normalized enthalpy vs Gd-DTPA/HA molar ratio 
for Gd-DTPA in 0.3% w/v HA (red circles), in 0.5% w/v HA (blue 
triangles) and in 0.7% w/v HA (magenta diamonds). The curves 
were shifted vertically for clarity; y-offset were set at 2 (red 
circles), 0 (blue triangles) and -10 (magenta diamonds).  
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Figure 1 bis. Titration curve of Gd-DTPA solution injected into 
water at 25 °C. 
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3.2 NMR study of DTPA interactions and water mobility in polymer solution  
Since previous ITC measurements reported by Gouin et al. 
117
 have shown no binding 
energy between free Gd
3+
 ions and HA, we hypothesize that polymer conformational 
changes are mainly induced by the presence of the chelating macromolecule, DTPA. 
NMR spectroscopy is used to confirm this hypothesis. NMR spectra are calculated for 
HA and DTPA solutions. We use only the DTPA without the metal ion since we are 
mostly interested in examining interactions between the polymer and the chelating 
macromolecule. 
Considering the spectra of the only DTPA and HA (Figure 2A-B), whose characteristic 
peaks are circled in blue and red respectively, the observations of DTPA/HA solutions 
at different molar ratios are reported (Figure 2C-I). The molar ratio ranges from 2 to 
100 and is obtained by decreasing the HA concentration from 150 to 10 µM. 
In Figure 2, it can be observed that the characteristic DTPA peak at 3.50 ppm (s, 2 H, 
CH2–COOH) is influenced by the presence of HA in solution. In fact, it seems to shift 
and reduce its intensity far more than the other peaks by increasing the HA 
concentration. As an example, the shift is evident by comparing Figure 2I, where the 
DTPA peak is highlighted in blue, with Figure 2C, where the signal is dramatically 
reduced. 
It results that an interaction between the two components of the system exists and 
generates changes in the NMR spectrum of the solution. 
Through NMR-DOSY, instead, we investigate how the presence of both HA and Gd-
DTPA can affect the mobility of water molecules. 
Figure 3 shows the normalized time-dependent self-diffusion coefficient of water in 
both polymer solutions (Figure 3A) and polymer-CA solutions (Figure 3B). For short 
diffusion delays, the measured self-diffusion coefficient D is nearly equal to the free 
self-diffusion coefficient D0 of water at 25°C (2.5·10
-9
 m
2
/s), since the molecules travel 
over a short distance and only few of them feel the surrounding macromolecules. As 
the diffusion time increases, more water molecules go through these restrictions and 
the self-diffusion coefficient reaches a plateau value.  
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We can hypothesize that the presence of Gd-DTPA compete with those HA-molecular 
sites beared by water molecules and that are responsible for polymer hydration and 
hydrogel formation. As highlighted with ITC results, the polymer conformation can be 
modified by the presence of Gd-DTPA, which could interplay with the water 
molecules and with the formation of hydrogen bonding. NMR-DOSY measurements 
are carried out to assess these hypothesized changes in water mobility. It can be 
observed that, in the case of the ternary system, the diffusivity of water beyond 
decreases, suggesting that the polymer-CA combination affects the water mobility 
more than the polymer itself. 
Figure 3A clearly shows that the water diffusion behaviour is affected by the polymer 
concentration. In particular, the diffusion coefficient decreases at increasing polymer 
concentration. Besides, Figure 3B shows the additional contribution of the CA to the 
water mobility. In fact, the presence of Gd-DTPA, even at relatively low 
concentrations (5 - 30 µM), can further reduce the value of the water self-diffusion 
coefficient for both short and long diffusion times. 
It is worth noting that low Gd-DTPA concentrations are chosen (Figure 3B) because 
Gd-DTPA is highly paramagnetic and it can interfere with NMR measurements 
118, 119
, 
while the HA concentrations (0.1 - 3% w/v) are slightly higher than those used in the 
ITC experiments to highlight and make more evident the differences in diffusion 
behaviour between samples. In particular, as illustrated in Figure 3B, a fixed polymer 
concentration of 1% w/v is selected to show the effect of CA on the diffusion of water 
molecules. 
A data comparison between ITC and NMR spectra confirms the hypothesized 
fundamental properties behind the concept of Hydrodenticity: the ability of Gd-DTPA 
to induce changes in polymer conformation and in water mobility. 
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Figure 2. (a) 
1
H NMR spectrum and chemical structure of DTPA; 
(b) 
1
H NMR spectrum and chemical structure of DTPA; (c – i) 1H 
NMR spectra of DTPA/HA solutions at different molar ratios, 
from DTPA/HA = 2 to DTPA/HA = 100. Characteristic peaks of 
DTPA and HA are highlighted in blue and red respectively.  
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Figure 3. (a) Normalized time dependent water self-diffusion 
coefficient in 0.1% w/v HA (squares), 1% w/v HA (triangles), 2% 
w/v HA (flipped triangles), 3% w/v HA (diamonds). (b) 
Normalized time dependent water self-diffusion coefficient in 1% 
w/v HA (triangles), 5 μM Gd-DTPA in 1% w/v HA (flipped 
triangles) and 30 μM Gd-DTPA in 1% w/v HA (stars). 
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3.3 Water dynamics within hydrated polymer matrix containing Gd-DTPA   
To analyse further the role of water mobility in the Hydrodenticity, a study of the 
dynamics and behaviour of water molecules is needed. Within hydrated polymer 
matrices (hydrogels), containing metal chelates, water molecules mediate polymer-CA 
interactions and, therefore, play a dual role: on one hand, the amount of absorbed water 
120, 121
 and its interaction with the hydrogel structure affects the chain motion of the 
hydrophilic polymer; on the other, the mobility of water molecules in the polymer 
matrix is responsible for the relaxometric properties of the CA. 
We investigate the water dynamics in water-HA systems, with and without Gd-DTPA, 
using the Differential Scanning Calorimetry (DSC). We focus on the thermal effects 
that the polymer (Figure 4A) and the CA (Figure 4B) have on the water dynamics. 
According to the literature, indeed, the crystallization of water changes with the 
polymer concentration and with the hydration degree 
111
. 
In Figure 4, thermograms of water-polymer systems at different HA concentrations 
(0.3 - 0.7% w/v) are displayed. We can observe that, during the cooling phase, the 
crystallization peaks shift to lower temperatures and lower enthalpy values. As 
expected, the enthalpy, given as the peak area, reaches its maximum value at the 
highest HA concentration (0.7% w/v). 
Figure 4B shows a comparison of melting (Tm) and crystallization (Tc) temperatures 
between HA solutions with and without Gd-DTPA (concentration range: 60 - 200 µM). 
It can be noted that the transition properties remained unaffected in presence of the 
CA, suggesting that the influence of the polymer on the thermal behaviour of water is 
predominant with respect to the CA at the selected concentration. 
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Figure 4. (a) DSC thermograms of HA at different concentrations 
(0.3, 0.5 and 0.7% w/v). (b) Melting (Tm) and crystallization (Tc) 
temperatures for free Gd-DTPA in water and HA solutions with 
and without CA.  
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3.4 Relaxation times, rates and relaxivity of the polymer matrix  
The existence of a water-mediated interaction between Gd-DTPA and HA, observed 
through ITC, NMR and DSC, and the effect of the polymer conformation on the 
characteristic correlation time of the metal chelate could explain the boosting of the 
relaxivity in the studied systems. 
Relaxometric properties are investigated by means of time-domain relaxometry on two 
different systems: non-crosslinked and crosslinked polymer matrix (0.5% w/v HA) 
containing Gd-DTPA. 
In the latter case, rheological and chemical-physical properties of polysaccharide can 
be modulated by changing the crosslinker (DVS) concentration, as known as 
crosslinking density. In fact, thanks to the presence of hydrophilic groups in the 
skeleton of HA, hydrogel is able to uptake a large amount of water. Under these 
conditions, water is in an abnormal aggregate state that influences the relaxivity of 
hydrated Gd-DTPA. 
Figure 5 shows the results of relaxometric measurements for the hydrogel system 
(0.5% w/v HA) studied by loading different concentration of Gd-DTPA. The hydrogel 
system is analysed and compared to the free Gd-DTPA solution. In particular, we 
display the increment in percentage of the paramagnetic relaxation as a function of Gd-
DTPA concentration. The increment in percentage of the relaxation enhancement has 
been calculated as follows (Equation 1): 
   
  (1) 
We find that the stronger is the interaction between Gd-DTPA and HA, the better is the 
MRI enhancement. Moreover, the crosslinked system is much more efficient than the 
non-crosslinked one. Indeed, in the crosslinked system, since the enhancement reaches 
a plateau at Gd-DTPA/HA molar ratio equal to 2.5 (i.e. at 300 µM of Gd-DTPA in 
0.5% w/v HA water solution), it is not necessary to overload the system with Gd-
DTPA in order to achieve higher relaxation. It is worth noting that, for both studies, 
with and without crosslinker, the Gd-DTPA concentration of 200 μM seems to 
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represent a threshold for the maximum effect of the hydrogel on the Gd-DTPA 
relaxation mechanism. 
 
 
 
 
Figure 5. Increment in longitudinal relaxation rate, R1, at different 
contrast agent concentrations (from 0 to 1 mM) for: free Gd-DTPA 
in water (black squares); Gd-DTPA in 0.5% w/v HA solution (blue 
filled triangles); Gd-DTPA in 0.5% w/v HA crosslinked with DVS 
(blue empty triangles). The R1 increment is calculated in 
percentage with respect to the corresponding R1 of Gd-DTPA in 
water. A fast increment in R1 is observed until a Gd-DTPA 
concentration equal to 300 µM. For higher Gd-DTPA 
concentrations, the R1 increment reaches a plateau. 
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Figure 6. Formation mechanism affects hydrogel network 
structure: schematic representation of: formation of a hydrogel of 
hyaluronic acid in water (top); complex HA-Gd-DTPA structure 
(middle); crosslinked hydrogel network containing the contrast 
agent (bottom). 
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Figure 6 displays a schematic representation of the hydrogel network formation, even 
in presence of the crosslinking agent, and its influence on the polymer conformation. 
We hypothesize that the boosting of Gd-DTPA relaxivity in a hydrogel matrix is due to 
a proper complexation between the polymer and the CA in solution, mediated by the 
water and further amplified by the addition of a crosslinker. It is confirmed that the 
reached equilibrium among osmotic pressure and elastodynamic forces of the polymer 
meshes and hydration degree of the CA in the matrix are able to tune finely the 
relaxometric properties of the metal chelates in the ternary system. The overall 
ensemble of these phenomena is defined as Hydrodenticity  
43
. 
 
4. Theory of the gado-mesh formation  
This work reports the use of polymer hydrogels for boosting the relaxivity of clinical 
relevant CAs. 
Results show that a spontaneous complexation exists between HA and Gd-DTPA due 
to thermodynamic interactions as demonstrated by both calorimetric and NMR 
measurements. It is already known that, in an aqueaous polymer solution, solvent 
affinity can alter polymer conformation by inducing a local solvation of the structure 
that influences the number of available conformations of the polymer chains. 
Moreover, the introduction of another soluble ionic component, such as Gd-DTPA, in 
the system can induce further changes in polymer conformation, detectable via diverse 
thermodynamic approaches 
122-125
. Based on our findings, we prove for the first time 
that these conformational changes, induced by the metal chelate, contribute to an 
increase in CA’s relaxivity. 
In order to tune the MRI enhancement, we exploit the versatile structural 
characteristics of HA. In fact, the high porosity of the hydrogel, which shows a mesh-
like structure, is controlled by varying the density of covalent crosslinking 
126, 127
. 
Moreover, the presence of negatively charged groups and the degree of crosslinking   
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influence water adsorption capacity and, thus, the relaxometric properties of the ternary 
system 
106
. 
Therefore, the presence of the hydrogel matrix can greatly amplify the magnetic 
properties of the encapsulated Gd-DTPA, suggesting a strong outer-sphere and second-
sphere contribution to the relaxivity. 
Based on these observations, we hypothesyze that increased relaxivity is mainly related 
to the creation of water domains or clusters (water compartments) around the CA 
within the polymer matrix. In fact, biopolymer systems contain intermolecular cavities 
that can be considered as molecular nano-domains in which various self-assembly 
processes can be implemented in principle 
128
. The formation of peculiar structures 
within these cavities can be associated with thermodynamic transitions and it is a 
characteristic of many metallopolymeric systems 
129, 130
. 
The sub-nanostructures, here defined “Gado-meshes”, are generated from a three-way 
interaction between HA, Gd-DTPA and water. The entrapment of the CA inside the 
hydrophilic matrix of HA results in a reduction of the rotational tumbling rate, due to 
an increase of the effective viscosity of the aqueous solution into the hydrogel matrix.  
At the same time, multiple CA-water interaction pathways occur between the 
exchangeable protons of the water molecules coordinated by the CA and the other 
water molecules freely moving within the hydrogel mesh or bonded to the polymer 
chains 
93, 105, 131
. 
Our “Gado-mesh” consists of highly relaxing Gd-water compartments spontaneously 
generated within the hydrogel matrix by the combination of these multiple physico-
chemical interactions. The so created nanostructure is composed of different water 
layers departing from the polymer chains that surround the Gd-molecules. It is known, 
in fact, that hydrated polysaccharides, such as HA, are characterized by the presence of 
multiple water layers, contiguous regions of variable water density within a 
polyelectrolyte solution 
132
, differing in their physical properties depending on the 
distance from the polysaccharide chain 
133
. The hydration process of HA generates: the 
“bound water layer”, which is the water fractions closely associated with the polymer 
matrix; the “unbound water layer”, made by the water molecules which are not directly   
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interacting with the polymer; and the “free water layer”, which resembles dynamics of 
pure water. In addition, the developed polymer network can be dependent not only on 
the water layers organization but also on other solute species, such as Gd-DTPA, 
altering the bound water layer with non-negligible effect on the HA conformation and 
dynamic 
134
. In the “Gado-mesh”, Gd-DTPA has a competitive behaviour with the 
respect of HA, similar to the cation shielding of the HA due to the presence of salts 
135
, 
and interposes itself between the water molecules around the HA, altering the bound 
water layer and generating water compartments with high MRI enhancing properties. 
The “Gado-mesh” influences the τR, τD and τM times through the action of the 
Hydrodenticity, whose effect is magnified by the crosslinking. Hydrodenticity, hence, 
refers to the status of the hydrated Gd-DTPA with the coordination water subjected to 
osmotic pressure deriving from elastodynamics equilibrium of swollen gels 
43, 136-141
. 
We hypothesize that the attainment of this equilibrium is reached when the normal 
energetic stability of the meshes is compromised by the presence of the Gd-DTPA and 
evolves to a new spontaneous equilibrium involving the formation of 
nanocompartments, so called “Gado-Meshes”, in which water is in an abnormal 
aggregate state that influences the relaxivity. Water molecules in the hydrogel matrix 
that are subjected to the effect of Hydrodenticity, are able to change their water 
dynamics and can mediate the hydrogel conformation and the physical and 
relaxometric properties of the metal chelate. 
 
5. Conclusion 
The properties of Hydrodenticity and its application to the nanomedicine field is 
reported. The explanation of this concept take place through several key aspects 
underlying biopolymer-CA’s interactions mediated by the water. A multidisciplinary 
approach is used: changes in polymer conformation and thermodynamic interactions of 
CAs and polymers in aqueous solutions are detected by isothermal calorimetric (ITC) 
measurements and later, these interactions are investigated at molecular level using 
NMR to better understand the involved the phenomena. Water molecular dynamics of   
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these systems is also studied by means of Differential Scanning Calorimetry (DSC). In 
order to observe relaxometric properties variations, it is monitored the MRI 
enhancement of the examined structures over all the experiments. 
The study of polymer-CA solutions reveals that thermodynamic interactions between 
biopolymers and CAs could be used to improve MRI Gd-based CA efficiency.             
In conclusion, this work proves that a new generation of more efficient CAs can be 
developed by exploiting the affinity between CAs and biopolymers. It can be done 
using biocompatible and clinical relevant CAs without their chemical modification as 
approved in the clinical practice.   
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CHAPTER II 
Hyaluronic Acid Nanoparticles: 
water-mediated nanostructures for 
enhanced MRI 
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1. Introduction 
Conventional drug preparations suffer from certain limitations like high dose and low 
availability, instability, and so on. As indicated in introduction section, an ideal 
nanocarrier for drug delivery applications should ﬁt the following proﬁle: 
biodegradable and biocompatible, able to recognize the target site, optimal biophysico-
chemical properties for drug loading, long circulation time, favorable therapeutic index 
and amenable to cost-effective scale-up for commercialization. The incorporation of 
these properties in one nanocarrier is the primary objective of nanomedicine
31
. 
In recent years, the scientific research has focused on biopolymers, biomolecules that 
are produced by living organisms (green plants, animals, bacteria and fungi)
142
. 
Characteristics such as biocompatibility, biodegradation and non-cytotoxicity make 
these material excellent candidates to be used in biomedical applications, in particular, 
to the development of therapeutic and diagnostic carriers.  
The main biopolymers used in biomedical field are collagen, chitin, chitosan (CS) and 
hyaluronic acid (HA)
143
. 
 HA, in particular,  has been extensively investigated in drug delivery applications, 
especially with the aim to treat cancer
88, 144
. As is well known, this is a biocompatible, 
biodegradable, non-toxic and non-inflammatory linear polysaccharide with high 
molecular weight made of repeating disaccharide units of D-glucuronic acid and N-
acetylglucosamine linked by β(1,4) and β(1,3)  glucosidic bonds88, 145. In physiological 
condition, it is widely distributed in extracellular matrix in the form of a sodium 
hyaluronate and shows negative charge
145
. In addition, due to its high capacity in 
retaining water, HA-based hydrogels are promising materials not only for tissue 
engineering but also nanomedicine
146
. Its short lifetime, however, necessitates 
chemical modiﬁcations and physical processing to improve its stability and maintain 
native biological functions
147, 148
. Physically crosslinked hydrogels have the advantages 
of  forming hydrogels without the addition of crosslinking agents, but they also have 
limitations in terms of pore size, chemical functionalization, and degradation time. 
Chemical crosslinking, instead, allows to realize a 3D-network with desirable   
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mechanical properties based on the nature of the chemical reagents and controllable 
degradation time
149
. An example of chemical crosslinking agent is represented by 
divinyl sulfone (DVS), which reacts with hydroxyl group on the backbone of HA to 
create intramolecular and intermolecular network
150-152
. 
Thus, chemically crosslinked networks have permanent junctions and these 
modifications can be introduced to provide a biomaterial with the desired functional 
properties
145
. In addition, the use of these biopolymers on nanoscale size allows further 
to optimize their properties depending on the specific application. In the end, in order 
to achieve the properties of interest, the mode of preparation plays a vital role and 
different techniques are currently available for HA-based micro- and nano- particles 
production. Among them, emulsification process has been greatly exploring
153
. Many 
products based on emulsions are widely used in pharmaceutical field as precursors to 
prepare carriers for diagnostic and drug delivery applications. Several scientific works 
report particles based on HA, prepared by water-in-oil (W/O) emulsion process, where 
the reaction take place within the aqueous droplets (containing HA) that are dispersed 
in a continuous organic phase with the aid of oil-soluble surfactants
154
.  
Yun and colleagues, for example, produce HA crosslinked microspheres (5–20 µm) for 
gene delivery application using a W/O microemulsion system as template, DVS as the 
crosslinker and an isooctane as continuous phase
155, 156
.  
Different hydrophilic HA NPs, instead, have been obtained using a diamine, 
2,2′(ethylenedioxy)bis(ethylamine), for cross-linking of the HA linear chains157, 158.  
In addition, also radical polymerization of HA (methacrylate groups are added to HA 
to obtain HA-glycidyl methacrylate conjugates) in an inverse emulsion of water in 
hexanes is made
159
. Then crosslinked HA particles (200–500 nm) are prepared  
dispersing the aqueous solution of thiolated HA in hexanes containing a surfactant 
mixture composed by different emulsifiers, such as Span 65, Span 80, and Tween 80. 
In this case, the resulting particles are loaded with siRNA and selectively endocytosed 
by cells expressing CD44 receptors on the surface. The release of siRNA in 
intracellular environment allow to silence the target genes
160
.  
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Further nanogels based on HA have been obtained by photochemical crosslinking of 
polymer confined in nanoemulsion
161
. HA chains, containing polymerizable 
methacrylate groups, are confined within W/O emulsion where the water droplets act 
as nanoreactors of the photopolymerization process mediated by UV.  Subsequently, 
intravenous docetaxel (DCT) delivery have been realized by Cho et al.
162
. In this case, 
HA conjugated with ceramide and Pluronic 85 (P85) give self-assembled nanoparticles 
(140 nm). In particular, P85 is added to provide stability to the micellar structure
163
, in 
fact, this copolymer is known for its low micellization and solubilization capacity to 
hydrophobic drugs. Thus, this type of delivery system depends on the copolymer 
type
162
. However, taking into account that the residues of oil and surfactant are 
prohibited for medical treatment and, often it is  difficult to completely remove these 
components from the final product, production processes without the use of oil and 
surfactant are performed by Fakhari and colleagues
164
.They synthesize crosslinked HA 
NPs via carbodiimide chemistry. In this case, EDC activates carboxyl groups available 
on HA and provides reactive intermediates (O-acylisourea derivatives) that react with 
two primary amines of adipic acid dihydrazide, forming a peptide bond resulting in the 
neighboring HA chains being chemically cross-linked.  
Then, two sequential additions of acetone are performed to break the strong hydrogen 
bonding between HA chains and HA-water molecules to release carboxyl groups for 
the cross-linking reaction is reached.  After the consumption of carboxyl groups by 
adipic acid dihydrazide, the cross-linked HA polymer chains become less soluble 
(hydrophilic) inducing transformation from coils to globules. 
As described in the Chapter I, several scientific works have been demonstrated that the 
polymer architecture affects some characteristic parameters of the metal chelate and 
tunes its relaxometric properties 
40, 43, 92, 103-105
. In fact, rational design of a new class of 
CAs, based on biopolymers (hydrogels), have received considerable attention in MRI 
diagnostic field and several strategies have been adopted to improve relaxivity without 
chemical modification of the commercial CAs.  
Moreover, it is clear that crosslinked biopolymers can have a significant role to 
overcome the limitations of clinically relevant CAs without their chemical   
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modification and as a compound in the design of advanced nanostructures with 
improved safety profile and switchable relaxometric properties. Indeed, it is known 
that the functional properties as well as the swelling behaviour of hydrogels are 
influenced by the hydration degree, which can be likely modulated by changing the 
chemical composition of the system 
106-112
. 
In this context, HA 
88
 is chosen and used as a model polymer because of its 
biocompatibility and high hydrophilicity and, the acquired knowledge about polymer-
CA interaction (see Chapter I) is applied to the concept of Hydrodenticity in order to 
obtain Gd-based polymer NPs with enhanced relaxometric properties. 
Here, it is reported a method based on single emulsion system (w/o) which has been 
developed to prepare HA-based NPs with a well-defined structure for MRI 
applications. The polymer chains are confined in the aqueous droplets of a water-in-oil 
nanoemulsion and crosslinked by chemical reactive (DVS) in the droplets as 
nanoreactors. The control of emulsion size distribution and stability are obtained by a 
careful choice of the emulsion composition and emulsification process. The conditions 
of the crosslinking reaction are modulated by changing the concentration, time of 
reaction and modality of addition of the DVS. The properties of the resulting NPs are 
analyzed using a combination of chemical-physical technique.  
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2. Experimental Section 
2.1 Materials 
All chemicals used are of analytical reagent grade quality and are employed as 
received. Sorbitan monooleate (Span
® 
80) (S80), Polyoxyethylenesorbitan trioleate 
(Tween
® 
85) (T85), Mineral oil (light oil, 0.8 gr/cm at 25°C), Divinyl sulfone (DVS, 
118.15 Da), Diethylenetriaminepentaacetic acid gadolinium(III) dihydrogen salt 
hydrate (Gd-DTPA, 547.57 Da), Sodium hydroxide pellets (NaOH), Acetone and 
Ethanol are purchased from Sigma Aldrich Chemical (Italy). Sodium Hyaluronate, 
with an average molecular weight of 850 kDa (purity 99%; Hyasis® 850P) and 42 
kDa, is respectively supplied by Novozymes Biopharma and Bohus Biotech (Sweden) 
as dry powder and used without purification. 
Magnevist
® 
(Bracco Imaging, Italy), a contrast agent commercially available, is used in 
this study. The water is purified by distillation, deionization, and reserve osmosis 
(Milli-Q Plus) and systematically used for sample preparation, purification and 
analysis. All experiments are repeated in triplicate and conducted at room temperature, 
25°C. 
 
2.2 Emulsion preparation 
The emulsions are prepared at different water to oil (W/O) ratio (10/90 and 20/80 v/v). 
Mineral oil is used as oil phase (or continuous phase, PC) and W/O emulsions are made 
by varying the concentration of surfactants for the PC and water phase (or dispersed 
phase, PD) and the concentration of NaOH (from 0 to 0.2 M) for the PD in order to 
obtain emulsion systems. In particular, a pair of non-ionic surfactants, Span-80 (S80) 
and Tween-85 (T85), are used to prepare mixtures with a range from 4.3 to 7.65 of 
HLB values. Depending on the initial HLB to be used, mixtures of S80 and T85 are 
pre-dissolved in the appropriate S80/T85 mass ratios (from 50/50 to 75/25) in PC and 
PD, respectively. PD containing T85 and NaOH, is added dropwise to PC and W/O 
emulsions are prepared using a high-shear homogenizer (Silverson L5M-A, Silverson   
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Machines Ltd, Waterside, UK). Homogenization of the Emulsion is performed from 
5000 to 7000 rpm for 10 min at room temperature (25°C). 
2.3 Temporal emulsion stability determination  
The stability of emulsions is evaluated, at regular time intervals, by visual observation, 
measuring the height of the phase separated by creaming in centrimeters as a function 
of the time. In addition, an optical characterization of emulsion stability made is using 
a Turbiscan (Turbiscan LabThermo) by static multiple light scattering (MLS), sending 
a light beam from an electroluminescent diode (λ=880 nm) through a cylindrical glass 
cell containing the sample. The emulsion sample without dilution is placed in a 
cylindrical glass cell and two synchronous optical sensors receive the light transmitted 
through the sample (180° from the incident light) and the light backscattered by the 
droplets in the sample (45° from the incident light). The optical reading head scans the 
height of the sample in the cell (about 40 mm), by acquiring transmission and 
backscattering data every 40 μm. Transmitted and backscattered light are monitored as 
a function of time and cell height for a period of 24 hours at an interval of 30 min at 
25°C. 
2.4 Preparation of DVS-crosslinked nanoparticles  
Based on these preliminary results, PD/PC ratio in all samples is set at 10/90 v/v. In 
particular, for the preparation of cross-linked NPs, HA powder (Mw = 850 kDa) is 
dissolved at different concentrations (from 0.1 to 0.5% w/v) under alkalyn condition 
(NaOH ranging from 0 to 0.2 M) by vigorous stirring at room temperature for 4 hours 
until a homogenous solution is obtained. Mineral oil and S80 (from 0.5 to 2% w/v) are 
separately mixed by stirring. PD is added drop-wise in the PC without stirring and all 
the components are completely mixed by homogenization at various times (5-15 
minutes) and speeds (5000 - 7000 rpm). Then, the cross-linking agent (DVS) is added 
to the final emulsion (40 ml), which is kept in agitation on a laboratory tube rotator for 
24 hours in order to obtain a homogeneous DVS distribution in the PD. To test DVS 
activity, various conditions of crosslinking reaction are explored: (1) at different DVS 
concentrations (from 0.01 to 0.5% v/v); (2) at three starting times of reaction   
- 61 - 
 
(beginning, during and post homogenization) and (3) at different temperatures (4 and 
25°C). 
The best experimental conditions for production of crosslinked HA-NPs are reported in 
Table 1. 
 
 
 
 
 
. 
Pd / Pc 
a)
 HA 
b)
 
[% w/v] 
NaOH 
[M] 
DVS
 c)
 
[% v/v] 
Span-80 
[% w/v] 
10 / 90 
0.1 
0 
0.1 
0.2 
0.045 1 0.25 
0 
0.1 
0.2 
0.5 
0 
0.1 
0.2 
a)
 Pd is the volume of the disperse phase, Pc is the volume of the continuous 
phase; 
b)
 Hyaluronic Acid;
 c)
 Divinyl Sulfone 
 
 
Table 1. Experimental conditions for production of HA-NPs  
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2.5 Loading of HA NPS with Contrast agents   
After identifying the protocol to obtain NPs, Gd-DTPA is chosen as CA and mixed in 
the PD before homogenization. Gd-loaded HA NPs (HA-Gd NPs) are prepared using 
different HA/CA mass ratios (1:1, 1:2 and 1:5). DVS are added post homogenization to 
the batch at room temperature using the same procedure reported above. 
2.6 Collection of the nanoparticles    
Recovery of the NPs and their separation from W/O emulsion system is made using 
dialysis and/or ultracentrifugation. For dialysis method, the obtained emulsion is 
placed in a pre-washed cellulose membrane tubing (Spectra/Por
®
 Dialysis Tubing, cut-
off of 25 kDa). Organic impurities (Mineral oil and S80) are removed dialyzing first 
against solvents as acetone and/or ethanol, and gradually against water. Dialyzing 
solutions are changed at regular time intervals. In the case of ultracentrifugation, 1 ml 
of the emulsion is added to 5 ml of ethanol and mixed for 2 hours. Then, this mix is 
centrifuged with an ultracentrifuge (Beckman-Coulter OPTIMA MAX-XP) at 55000 
rpm for 20 min at 15°C. The resulting pellet is washed twice and resuspended in 
MilliQ water. The second step of ultracentrifugation (70000 rpm, 10 min, 15°C) is 
applied to the pellet in order to obtain purified NPs. 
2.7 Characterization of the nanoparticles     
The chemical modifications of polymer by DVS are identified by infrared spectroscopy 
(Thermo). The characteristic peaks for DVS are: 1310 cm-1 (S=O asymmetric 
stretching vibrations), 1130 cm-1 (S=O symmetric stretching vibrations) and 794 cm-1 
(S−C stretching vibrations) and through the ether bond at 1255 cm-1 (C−O−C 
stretching vibrations). 
To determine size distribution of NPs, dynamic light scattering (DLS) are performed 
using a Zetasizer S-90 1000 HS (Malvern Instruments, UK). 
All samples are diluted (1:10) with deionized water to prevent the effects of multiple 
scattering. The measurement temperature is set at 25°C. The morphology and size of 
NPs are investigated using a ULTRA PLUS field emission Scanning Electron 
microscope (FE-SEM Carl Zeiss, Oberkochen, Germany) and a Transmission Electron   
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microscopy (TEM, TECNAI). In the first case, the samples are coated with gold (7 
nm).                            
2.8 Determination of Gadolinium loading by ICP-MS      
The quantitative determination of loaded Gd in HA NPs is assessed by ICP-MS 
(NexION 350, Perkin Elmer) without any previous digestion processes. For all 
examinations, purified NP suspensions are used. The non-encapsulated Gd-complexes 
are separated from the NPs by high speed centrifugation (55000 rpm, 20 min, 15 °C). 
2.9  MRI Testing      
To explore the potential of Gd-loaded HA NPs as MRI contrast agent, MRI in vitro test 
is performed at two different magnetic fields, 1.5 T and 3 T MR (Philips Achieva) 
using Sense Head 8 coil. The T1-weighted MR images of HA NPs, unloaded and 
loaded with Gd-DTPA at different concentrations using an inversion recovery 
sequence are measured with the following parameters: TR = 2500 ms; TE = 12 ms; TI 
= 50, 100, 200, 400, 800, 1100, 1800 ms; FOV= 180x146 mm; slice thickness = 4 mm, 
acquisition matrix = 360x292. 
The signal intensity of the samples is measured on the obtained T1-weighted MR 
images and compared to Gd-DTPA. 
2.10 NMR dispersion measurements       
The proton 1/T1 NMRD profiles are measured using a fast-field-cycling Stelar 
SmarTracer relaxometer over a continuum of magnetic field strengths from 0.00024 to 
0.25 T (which correspond to 0.01 - 10 MHz proton Larmor frequencies). The 
uncertainty of these measurements is less than 1%. Additional data points in the range 
15 - 70 MHz are obtained using a Stelar Relaxometer and a Bruker WP80 NMR 
electromagnet adapted to variable-field measurements (15 - 80 MHz proton Larmor 
frequency). 
 
2.11 In vivo tests and cytoxicity evaluation of HA-based Nanoparticles 
After excluding the toxicity in vitro, animal experiments are carried out and, a total of 
9 mice (body weight about 20 g, C57 - Balb/c mice model) are used. Unloaded and   
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loaded HA NPs are prepared using physiological saline solution and Magnevist
®
 is 
used as control. In each solution, the final Gd concentration is the same.                      
The NPs formulations (final volume: 200 µl) are injected into the tail veins of mice. 
All studies are performed with mice under general anesthesia, obtained with an 
intraperitoneal injection of tribromoethanol solution at a final concentration of 12.5 
mg/mL and administered at a dose of about 250 mg/kg. Once anesthetized, mice were 
prepared for venous cannulation by bathing the whole tail in tap water warmed at 39 
°C to obtain proper vasodilation. A lab-made catheter, consisting of a 30 G needle 
mounted on a polyethylene tube, is delicately advanced in one of the lateral caudal 
veins, until blood could be seen in the tube. Hence, two-three drops of surgical glue 
were spilled on the needle /tail interface area and let dry. The tube is flushed with 20 
µL of a heparinized solution and the tip of the tube is closed to avoid further bleeding. 
The mice are then positioned on magnetic compatible bedding within a head coil and 
the baseline acquisition was performed. Then, 200 µL of the CA solution are slowly 
injected, following any eventual reaction of the mouse or any change in the respiratory 
pattern. Acquisition are performed every 10 minutes till one hour post injection, and 
then after 3, 6, 8 and 24 hr.         
Images are taken using the PET/MRI 3T Siemens instrumentation applying an 
Inversion Recovery (IR) sequence (VOF= 100x75 mm; slice thickness=1.2 mm without 
GAP, contiguous slice, acquisition matrix=192x144; Averages: 6; Turbo spin-echo; 
Sequence duration: 10 minutes -36 seconds; Signal to Noise Ratio: 1; Spatial 
Resolution: 0.5 x 0.5; TR: 550; TE: 11). A basal acquisition has been conducted for all 
subjects before the injection protocol. The DICOM files of each acquisition were 
stored on an external unit. The files were imported in dedicated software for imaging 
analysis (OsiriX© Lite, Pixmeo SARL, Bernex, Switzerland). A circular region of 
interest (ROI) of about 2 mm
2
 is drawn and then saved, to be used in the analysis of all 
images. The anatomic areas studied are: renal cortices and medullas, the urinary 
bladder, the salivary glands. The mean intensity obtained for each organ (IO) is 
normalized to the mean muscle intensity (IM) applying the formula: IOnorm = IO/IM, 
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and the result was used to calculate the percentage of contrast enhancement (% CE) 
according to Corbin et al.
190
 % CE = (Ipost – Ipre) / Ipre * 100.  
After the MRI scans, in order to analyze the quantitative distribution of the HA NPs in 
vivo, the mice are sacrificed at different time points (2 hr, 4 hr, 24 hr, 48 hr and 40 
days) after injection. The blood, heart, spleen, lungs and liver are collected and 
immediately washed twice with physiological saline solution. Experiments have been 
repeated in triplicate. Quantitative analysis has been made by digesting and 
homogenizing the organ with nitric acid at 100°C for at least 3 hr. Later, NPS are 
resuspended in a solution of deionized (DI) water at a concentration of 150,000 
particles/mL. All data are collected and processed using the Syngistix Nano 
Application Module.  
 
3. Results and Discussion 
3.1 Case study: production of polymer particles based on Hydrodenticity  
Recent recommendations from Food and Drug Administration (FDA) and European 
Medicine Agency (EMA) about the Gd deposition in the brain and other tissues have 
highlighted the importance to design polymer biocompatible NPs with enhanced 
relaxivity without chemical modification of the clinical relevant CAs 
28, 165
. Thus, 
crosslinked NPs formed by HA, a biodegradable, biocompatible, non-toxic, non-
immunogenic and non-inflammatory linear polysaccharide 
166
, could represent a 
successful candidate among nanovectors for MRI applications 
38
. Indeed, in the last 
decades, it is undisputed the growing research interest toward the therapeutic action of 
HA and in developing new diagnostic tools based on this polymer 
38
. In this work, 
starting from the above-presented results, we aim to apply the Hydrodencity in the 
design of biocompatible hydrogel nanostructures to obtain improved relaxometric 
properties. We propose a concrete example of the concept of Hydrodenticity applied to 
the production of crosslinked HA NPs for MRI, loaded with Gd-DTPA. An emulsion-
based method is used to obtain stable W/O nanoemulsions as templates.  
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3.2 Study of emulsion stability 
Stable W/O emulsions are prepared by stirring appropriate amounts of oil phase 
(Mineral oil) and aqueous phase containing different concentrations of Span-80 (S80) 
or S80 with Tween-85 (S80/T85). The pH, ranging from 12 to 14 is adjusted by adding 
appropriate amounts of NaOH from a stock solution (0.2 M). Further details are 
reported in the Materials and Method Section. As expected, in the absence of any 
surfactant, W/O emulsions prepared in the same conditions split very rapidly in two 
phases due to their unfavourable thermo-dynamic state. Visual comparison, 
turbidimetry and backscattering are successfully used to study emulsion stability 
(Figure 7 and 8) 
167
.  
 
 
 
 
Figure 7. Photografic image of the appearance of 
emulsions at 25 °C by the effect of increasing 
concentration of surfactants and NaOH [(a) 0 M; (b) 0.1 M; 
(c) 0.2 M] on stability of W/O (10/90 and 20/80) emulsion 
after 12 h. 
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 Figure 8. Trasmission and backscattering spectra of W/O 
(10/90) emulsion (total volume, 20 ml; 5000 rpm, 10 min) 
with 1% w/v of S80 without (a) and with (b) 0.2 M NaOH.  
- 68 - 
 
Comparing emulsions obtained at different W/O ratio, 10:90 and 20:80, but at same 
concentration of surfactant, the stability is more extended for emulsions with lower 
water content. In particular, a formulation 10/90 W/O volume ratio containing S80 (1% 
w/v) and T85 (0.5 % w/v) resulted the more stable. However, even though the stability 
of the emulsion is crucial to reduce polydispersity, an alkaline environment (addition 
of NaOH) is necessary for the crosslinking reaction to take place. Indeed, Balazs and 
Leshchiner 
168
 showed that the crosslinking reaction starts shortly after addition of 
DVS (5 - 10 min) and, that, 1 hour is sufficient for the completion of the reaction.
169, 170
 
On the basis of these requirements, to conduct the experimental campaign, we select 
the formulation with S80 (1% w/v) and NaOH (0.2 M) as the optimal trade-off to 
obtain an emulsion stable for at least 3 hours (Figure 7 and 8), enough for the DVS to 
react. 
3.3 Preparation of DVS-crosslinked nanoparticles with and without CA  
The exploitation of the best process conditions to design biocompatible nanostructures 
based on Hydrodenticity and control their relaxation parameters for MRI application is 
reported. In particular, the effect of the homogenization, HA concentration and the role 
of the crosslinking reaction is analysed. Different experimental parameters and 
conditions are tested and details are reported in the Materials and Methods section. A 
preliminary mixing is performed at 5000 or 7000 rpm for 10 min, by keeping constant 
the temperature at 25 °C. A 5000 rpm speed is preferred to avoid and uncontrolled 
increasing of the temperature. 
After the homogenization, a crosslinking reaction is performed at high pH values (12 - 
14) and creates sulfonyl bis-ethyl linkages between the hydroxyl groups of HA 
171
. 
This crosslinking method has the advantage of occurring at room temperature, which 
limits the degradation of HA in alkaline solutions. Even though the starting material 
DVS is highly reactive and toxic, the biocompatibility of the HA-DVS hydrogels are 
confirmed by histological analysis 
172
. 
In our protocol, a study of the modalities of injection of the crosslinking agent at 
different steps of the homogenization process has shown that only when DVS is added 
after the homogenization step spherical NPs are obtained. On the contrary, when the   
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addition of the crosslinker is performed at any time point during the homogenization 
phase, a shear stress behavior of the polymer phase, interfering with the formation of 
that particles, is observed (Figure 9). 
 
 
 
 
Figure 9. Optimization of HA NPs synthesis. SEM images of 
crosslinked nanoparticles (0.5% w/v HA; 18 µL (0.045% v/v) 
of DVS; 40 mL of W/O (10/90) emulsion; 5000 rpm, 10 min, 
RT, using high-shear homogenizer) under various conditions: 
HA’s concentration, (a) 0,5% w/v; (b) 0,25% w/v and (c) 
0,1% w/v. Start of reaction, (d) during, (e) end and (f) after 
homogenization. DVS’s concentration: (g) 18 µL and (h) 
200 µL (0.5% v/v). 
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The best experimental condition for production of crosslinked NPs is reached at 
0.045% v/v DVS (Table 1). 
Based on these results and using the same process conditions, loaded NPs are obtained 
by adding the CA in the water phase of the emulsion. Among several FDA approved 
CAs, we have chosen to encapsulate a Gd chelated, Gd-DTPA (9.13 mM). 
3.4 Purification and characterization of HA-NPs  
Ultracentrifugation (UC) and dialysis are performed to purify HA NPs. Dynamic Light 
Scattering (DLS) measurements are made on aqueous dilute NP suspension (1:10). The 
smaller NPs’ size without CA (217.57 ± 34.65 nm) is obtained at 0.25% w/v of HA 
solution. At higher polymer concentration (0.5% w/v) particle size is higher (401.67± 
77,65 nm), while the formulation with 0.1% w/v HA shows a reverse phenomenon 
with larger particles (760.15 ± 86 nm), probably due to less stability of the nuclei that 
tend to coalesce. When Gd-DTPA is added to the process, the particle size at HA 
0.25% w/v is slightly increased (258.77 ± 15.65 nm) for the same process conditions. 
After purification, NPs are investigated by electron microscopy techniques (SEM and 
TEM). The morphology of the NPs observed revealed that the particles are spherical in 
shape and monodisperse (Figure 10). 
In addition, to confirm that the crosslinking reaction is successfully completed, IR 
analysis are performed. The chemical modiﬁcations of HA are identiﬁed in IR spectra 
of the HA NPs by the presence of characteristic peaks for DVS that appear between 
1384 and 1280 cm-1, which are attributed to the sulfone group (vSO2=1350, 1310 cm-
1). 
Loading Capability (LC) and Encapsulation Efficiency (EE) is determined through 
ICP-MS by comparing the theoretical amount initially used to prepare the particles and 
the Gd encapsulated in the system after ultracentrifugation. The higher encapsulation 
results for 0.25 % w/v HA (1:2 w/w HA/Gd-DTPA ratio). Results show that probably 
ionic nature of Gd-DTPA impacts on its encapsulation. The zeta potential value of the 
0.25% HA-NPs, with and without CA, indicate that they had a negatively charged 
surface (-37.4 ± 1.34 mV and -31.8 ± 0.88 mV, respectively), due to the carboxylic 
group of HA.  
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Figure 10. SEM images of crosslinked HA nanoparticles 
(0.5% w/v of HA; 1% w/v of S80; 0.045% v/v of DVS) 
without (a) and with (b) contrast agent. 
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3.5 Relaxivity studies  
T1 and T2 measurements at 60 MHz (1.5 Tesla) and 120 MHz (3 Tesla): Relaxivity 
and relaxation times are measured for both unloaded and loaded NPs and compared 
with free Gd-DTPA solution. Measurements are performed on a 120 MHz (3 Tesla) 
MRI system and on a 60 MHz (1.5 T) benchtop relaxometer. 
Relaxivity results obtained at 120 MHz are presented on a per millimolar Gd basis in 
Figure 11a and show a maximum r1 of 33.3 s-1mM-1 (i.e. 10 times higher compared to 
free Gd-DTPA). Even though all the proposed formulations of Gd-DTPA-loaded HA 
nanostructures show an increase of the r1 signal, as reported in Figure 11a, the highest 
boosting of the relaxivity is provided by the NPs obtained using the formulation at 
0.25% HA and 1:2 w/w HA/Gd-DTPA (Figure 11 A-C). 
T1 relaxation time distributions at 37°C and 60 MHz are investigated for loaded and 
unloaded NPs (HA at 0.25% w/v) as well as for free Gd-DTPA solution (Figure 11 D). 
Compared to the 200 µM free Gd-DTPA solution, which shows a broad distribution 
around 1000 ms, NPs loaded with 200 µM Gd-DTPA exhibit an excellent T1 
distribution with a sharp peak centered below 500 ms. Gd concentration within loaded 
NPs was determined through Inductively Coupled Plasma Mass Spectrometry (ICP-
MS). 
Loaded NPs perform far better even compared to the unloaded ones, whose distribution 
appears to be broad and centered around 2800 ms. 
It is worth mentioning that, compared to T1 distribution for bulk water (3600 ms), 
unloaded NPs’ distribution shows that a slight contribution to the longitudinal 
relaxivity is ascribable to the crosslinked polymer nanostructure, which is able by itself 
to tune the water mobility for a non-nanostructured material. The contribution, 
therefore, to the overall relaxivity is further enhanced in the ternary system, thanks to 
the water-mediated interaction between the polymer and metal chelate.  
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Figure 11. (a) Relaxivity values r1 determined at magnetic field 
strengths of 3T for different set of HA-NPs with respect to free 
Gd-DTPA in water. (b) Longitudinal relaxation rate (1/T1) versus 
Gd-DTPA concentration for free Gd-DTPA in water and for HA-
NPs at different polymer concentrations loaded with Gd-DTPA. (c) 
T1-weighted images of Gd-DTPA, unloaded (used as control) and 
HA-NPs at different polymer concentrations loaded with Gd-
DTPA. All samples are imaged at 3T, 25°C, using standard spin 
echo (SE) sequence. (d) Distribution of longitudinal relaxation 
times of (T1) of 200 μM Gd-DTPA in water (squares), unloaded 
0.25% HA-NPs (circles) and 0.25% HA-NPs loaded with 200 μM 
Gd-DTPA (triangles). 
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3.6 Modeling of NMR dispersion: NMRD profile   
The NMRD profiles as function of the static magnetic field of the aqueous solutions of 
Gd-DTPA and loaded and unloaded NPs (Figure 12) are set up in order to establish the 
effects caused by Hydrodenticity functionalities on the parameters that determine the 
observed relaxivities. The longitudinal relaxation rates are recorded at 37°C as a 
function of resonance frequency and according to NP Gd-loading obtained by ICP-MS. 
The NMRD experimental curve for free Gd-DTPA shows a plateau in longitudinal 
relaxivity at low fields and significantly decreases as the applied magnetic field 
increases starting from 1 MHz. Conversely, longitudinal relaxivity (r1) for loaded NPs 
(HA at 0.25% w/v) is characterized by the presence of a low-field plateau and a 
gradual increase starting from 10 MHz, reaching a “dispersion peak” between 60 and 
70 MHz. The same peak and trend in the high field region (20 – 70 MHz) is observed 
for both at 25°C and 37°C. As a control, unloaded NPs do not exhibit increase in 
relaxivity in this field region, confirming that the nanohydrogel structure containing 
Gd-DTPA contributes to slowing the chelator's tumbling motion and allows water 
exchange thanks to its hydrophilic properties, as hypothesized in the concept of 
Hydrodenticity. 
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Figure 12. NMRD profiles showing relaxivity of Gd-DTPA in 
water (squares), unloaded 0.25% HA-NPs (circles), Gd-loaded 
0.25% HA-NPs at 25°C (triangles) and 37°C (flipped triangles).   
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3.7 In vivo analysis and cytotoxicity evaluation of HA NPs 
In vivo MRI analysis has been conducted on 3T MRI instrumentation for all subjects 
before the injection protocol as reported in the experimental section.                          
Figure 13 and 14 show the coronal view MRI images of a mouse (C57 - Balb/c murine 
model) injected with CA (Gd-DTPA, 800 µM) and loaded HA NPs (99 µM) 
respectively.                                     
It is no observed adverse effects during the experiments and, considering the renal 
excretion of the CA, the kidney appear lighter than other tissues. In particular, the 
bladder becomes lighter after 6 min from injection and remains high to 1 h. After this 
time, the signal strength of the whole mice body tends to the normality.                                      
In the case of loaded HA NPs injection, the signal intensity in the kidney immediately 
increases. The enhanced signal intensity is detectable after 3 min and remains visible 
to 1 h after intravenous injection.                              
It is also important to notice that MRI signal in the kidneys,  in the case of loaded HA 
NPs compared to the free CA, has the higher persistence (Figure 15).                  
The accumulation of the metal within the organs is measured by ICP-MS, after 
homogenization and digestion as reported in the Experimental Section of this chapter. 
Further evaluations are under investigation. These preliminary in vivo tests show there 
is an enhancement of the MRI signal and confirm the stability of HA NPs.  
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Figure 13. In vivo coronal view MRI images of a mouse after 
intravenous injection of  Gd-DTPA (800 µM). Qualitative 
Image Analysis for bladder at different time intervals: A) 
before injection of Gd-DTPA; B) after 6 minutes and C) after 
30 minutes from injection of Gd-DTPA. 
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Figure 14. In vivo coronal view MRI images of a mouse after 
intravenous injection of  loaded HA NPs  (99 µM). Qualitative 
Image Analysis for bladder at different time intervals: A) 
before injection of loaded HA NPs; B) after 6 minutes and C) 
after 60 minutes from injection of loaded HA NPs.  
- 79 - 
 
 
 
 
 
 
 
 
Figure 15. Biodistribution for kidney and bladder of  CA and 
loaded HA NPs at different concentration after 1 h form 
injection.  
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4. Conclusion 
The optimal conditions to combine a CA with a hydrophilic biopolymer are identified 
and applied to the nanoscale in order to produce nanostructures of biomedical interest 
with high relaxivity. In particular, stable crosslinked HA NPs encapsulating Gd-DTPA 
are successfully prepared using a method that exploits the use of W/O nanoemulsions 
as templates. The aqueous emulsion droplets are shown to provide a good environment 
for the formation of the NPs and seemed to limit efficiently their size. NPs collected 
from the emulsion droplets using a purification procedure showed a size of about 200 
nm and spherical shape. The conditions of the herein presented protocol to produce 
these biocompatible NPs offer advantages for the encapsulation of a broad-spectrum of 
biomolecules and provide a potential synthetic route to design a wide range of highly 
efficient nanostructured MRI CAs, letting the surface available for possible 
functionalization. In conclusion, this work proves that a new generation of more 
efficient CAs can be developed. It can be done using biocompatible and clinical 
relevant CAs without their chemical modification as approved in the clinical practice. 
Furthermore, the size of the resulting NPs is in a range that makes them suitable for 
delivery to cells and certain tissues and further increase in relaxivity can be potentially 
achieved by tuning the system to the most efficient structure by choosing the correct 
biopolymer-CA combination and optimizing concentration and crosslinking degree of 
the structure. From a biomedical point of view, the possibility to tune relaxometric 
properties of CAs by controlling hydrogel structural parameters can pave the way to 
new advancements in the design of nanovectors for diagnosis and therapy. In addition, 
preliminary studies about toxicity, in vivo biodistribution and MRI acquisition 
highlight the powerful effect of the produced nanostructures for application in clinical 
imaging. 
Despite the promising achievements, further studies are needed to carry out a deeper 
investigation and a full validation our intriguing hypothesis.  
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CHAPTER III  
Functionalized HA NPs: the case 
study of a B-cell lymphoma. 
  
- 82 - 
 
1.  Introduction 
 
Cancer is the most common cause of death in industrialized countries
173
 and, in certain 
cases, the patient remains asymptotic. Actually, the choice of the right therapeutic 
approach is subject to an accurate and reliable diagnosis in order to identify the 
primary site of tumour and potential dissemination of the disease to distant sites in the 
body
174
. In this context, diagnostic radiology and nuclear medicine studies play 
important roles in clinical management of cancer
175
. 
In particular, in the case of lymphoma neoplasms, which expression is variable, the 
diagnose from imaging is difficult
176
. 
In particular, lymphomas are lymphoproliferative diseases composed by malignant B 
and T cells, which arise predominantly in the lymphoid tissues during the course of 
normal development
177
. The most common form of lymphomas, Non-Hodgkin 
Lymphomas (NHLs), can originate from T cells, or more frequently, very distinct 
malignancies like classical Hodgkin lymphoma (cHL) and multiple myeloma (MM) 
arise from B lymphocytes with various stages of differentiation. Therefore, the early 
detection of this pathology affects the therapy of patients
178
.        
The pivotal role of techniques such as CT and MRI are undoubtedly first-line 
modalities to be employed in patients affected by cancer. However, they rely on 
anatomical landmarks (i.e. morphological alterations due to the tumour) to identify 
tumour involvement and this leaves the clinicians with a grey area of cases that require 
further investigations (i.e. PET imaging)
179
.  
Conventional imaging with CT
5
, in the case of lymphoma, shows the technical limits 
of CT are: (1) limited accuracy at inizial staging for assessing lymphoma in small 
nodes (< to 1.5 cm), bone marrow, or various extranodal sites; (2) inability to 
differentiate active disease within a residual mass; and (3) limited ability to assess 
early response to treatment although more aggresive, but also potentially more toxic 
treatment
5, 180
. As a result of these limitations, several  lesions seen on PET images may 
not be visible on CT examinations and, overall, PET examinations are more sensitive 
in these  evaluation. In fact, unlike CT, which shows anatomic details, 
18
F-FDG PET 
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can play a significant role in the staging of patients with lymphoma 
181
. In fact, high-
grade tumours demonstrate greater metabolic activity (and greater 
18
F-FDG 
accumulation) than low grade tumours. Unfortunately, variable aggressiveness and 
makes it difficult to diagnose them from imaging. In addition, the future goal of 
imaging consists of optimal staging method for non-invasively lymphoma detection. 
In this scenario, MRI is recently emerged for monitoring of pathological progression 
and evaluation efficacy of treatments
3, 4, 182, 183. MRI’s susceptibility to artifacts of 
motion and organ pulsation means that it has certain limitations for the detection, for 
example, of lymph node metastases, particularly in the thorax and diaphragm region, 
leading to reduced diagnostic accuracy (79% to 82%). In addition, the lack of 
metabolic information in borderline large lesions ≤ 1 cm in diameter constitutes a 
disadvantage versus multimodal imaging in dignity assessment
184
.               
An interesting strategy to increase the degree of information resulting from the MRI 
analysis could be to associate CAs with nanovectors for diagnostic purpose. In fact, if 
designed appropriately, these nanovectors may act as a drug vehicle able to target 
tumor cells protecting the active molecules from inactivation during their transport. 
The physico-chemical characteristics (particle size, surface charge, surface coating, 
stability) of the NPs allow the redirection and the concentration of the marker at the 
site of interest. Indeed, nanovectors with ligand-decorated surface enhance selective 
cellular uptake (‘active targeting’)185. 
Currently, even if in vitro studies has received considerable attention in recent years 
the clinical translation of NPs remain laborious.In particular, MNPs functionalized 
with anti-CD20 antibodies, are made and tested on two murine cell lines. The results 
indicate that receptor recognition ability of the antibody (< 95%) is retained after 
conjugation with MNPs proving that anti-CD20-MNPs can be used for sensitive 
detection of cancer cells.  
Kozlowska et al.
186
, instead, synthesize liposomes loaded with Gd ions using different 
membrane-incorporated chelating lipids and functionalized with monoclonal anti-
CD138 (syndecan-1) antibody for multiple myeloma and non Hodgkin’s lymphoma 
diagnosis. In this case, the use of the polychelating amphiphilic polymer increases both 
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the Gd content and the longitudinal relaxivity of the Gd-loaded liposomes as compared 
to commercial CA (Gd-DTPA). 
To selectively target site-specific markers, several approaches have been used, and 
among these, mimotopes are particularly interesting. Mimotopes are amino-acidic 
sequences that are able to mimic the three-dimensional structure of the original 
antigenic epitope
187
. In addition, these molecules can be conjugated to a variety of 
nanostructures, as recently reported by Torino et al.
188
,  and act as vehicles for 
therapeutic and/or  diagnostic agents with extreme specificity. 
An example of mimotope is represented by peptide A20-36 (pA20-36) that binds the 
Ig-BCR of B-cell lymphoma (A20) cells
189
. 
In this context, the current section reports the use of biocompatible HA-based NPs, 
produced as indicated in Chapter II, that are conjugated with pA20-36 for in vitro and 
in vivo evaluations. In vivo experiments are performed in accordance with the 
European guidelines of the2010/63/EU Directive on the protection of animals used 
inscientific studies, after Italian Ministry of Health approval, Protocol no. 49/2015-PR 
e n° 50/201. 
 
2. Experimental Section 
2.1 Materials 
EDC (N-(3Dimethylaminopropyl)-N′-ethylcarbodiimide, MW=191.70), NHS (N-
Hydroxysuccinimide, MW=115.09), Streptavidin (1mg/ml), QuantiProTM BCA assay 
kit, the WST-1 assay and Plasma from human P953 are purchased from Sigma Aldrich 
Co. Cy7- PEG1KDa-NH2, and Fitc-PEG1KDa-NH2 are purchased from Nanocs Inc. 
Peptide pA20-36 (amino acids sequence: EYVNCDNLVGNCVIRG, MW=1922, 1 
mg/ml) and peptide pA20-S (amino acids sequence: DQEWCKTISFEPCLEN, 
MW=1067, 1 mg/ml) are purchased from CASLO ApS.   
Polystirene NPs are purchased by Thermo and used fo PEG-FITC quantification.  
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2.2 Functionalization of HA NPs 
The strategy of NPs functionalization provides the following steps: 1) chemical 
modification of HA NPs; 2) covalent binding of proteins (Indirect Conjugation) 
and/or peptides (Direct Conjugation); 3) formation of “HA NPs-Protein-Peptide” or 
“HA NPs-Peptide” conjugates; 4) characterization of the products and analysis of 
critical control points. 
The reactions are schematically represented in figure 16. 
 
 
 
Figure 16. Representation of strategy to conjugate the NPs 
with selected peptides. 
 
2.2.1Quantification of carboxyl groups on the surface of crosslinked HA NPs 
Back tritation method is performed to directly quantify carboxylic groups on the 
surface of particles. 0.1 mg/ml of NPs are dispersed in NaOH solution (20 ml of 0.01 
M ) and HCl is used as the tritant agent. The molar concentration of carboxylic sites 
are obtained from difference in concentration at equivalent point between HCl and 
NaOH.  
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2.2.2 Direct conjugation of HA NPs 
Unloaded and loaded NPs, produced as indicated in Chapter III, are centrifuged, 
collected and characterised by SEM analysis. The surface of the NPs has been 
activated using an amidation reaction with EDC (0.02 M) and NHS (0.01 M) for 10 
minutes in water solution on rotary shaker
145
. The peptides, pA20-S and pA20-36 
(500µl), previously deactivated with TEA, is added directly to the reaction. Reactions 
are kept in agitation by a rotating shaker for 4 hours and, finally a further purification 
is carried out to remove the excess of peptides. The collected material is resuspended 
in PBS solution. 
2.2.3 Indirect conjugation streptavidin-biotin-peptide 
The surface of the NPs has been activated using an amidation reaction with EDC (0.02 
M) and NHS (0.01 M) for 10 minutes in water solution on rotary shaker
145
. Then, the 
samples are centrifuged at 70,000 rpm, 15° C, 10 minutes and the resulting pellets are 
resuspended in PBS solution. 
Subsequently, the STR protein (1.5 mg/ml) is added and allowed to react overnight on 
rotary shaker. After removal of the excess reagents by ultracentrifugation method, the 
pA20-36 (150 µg/mL) to be conjugated is added to the resulting pellets. In addition, it 
is also tested the peptide A20-S as negative control and pA20-36 at the same 
concentration reported above of. The reaction is conducted for 4 hours on rotary 
shaker, and finally a further purification is carried out to remove the excess of peptides. 
The collected material is resuspended in PBS solution.  
 
2.2.4 Bicinchoninic Acid Assay 
The bicinchoninic acid assay (BCA assay, sensitivity: 0.5 µg/ml), also known as the 
Smith assay, is used for quantitation of total protein in a sample, in this case allows to 
measure the concentration of the peptide on the surface of the HA NPs. It is based on 
the principle that under alkaline conditions the copper Cu
+2
 ions form a complex with 
peptide bonds of proteins and are reduced to Cu
+1
. In addition, the presence of a 
specific chemical compound (purple colour) allows to quantify the amount of protein 
present in the sample of interest. The intensity variation is determined by absorbance   
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spectrophotometer measurement at 562 nm (enspire Multimode Plate Reader 
PerkinElmer).150 µL of the HA NPs suspension are reacted with equal amount of 
working reagent solution and the mixture is incubated at 37°C for 2 h. The results are 
compared with a bovine serum albumin (BSA) calibration curve and the concentration 
value is then extrapolated by a straight line of calibration built using BSA samples of 
known concentration (0 - 40 µg/mL). All measurements are performed in triplicate. 
2.2.5 Cell Lines 
A20 is a murine cell line derived from a spontaneously arising tumor in an aged 
BALB/c mouse. It pathologically mimics the characteristics of human diffuse large B-
cell lymphoma
211
. The 5T33 murine myeloma (5T33MM) cells are used as control. 
The cell lines are kindly provided by Prof C. Palmieri (University of Catanzaro, Italy). 
The cell lines are grown in suspension culture with Roswell Park Memorial Institute 
(RPMI) 1640 medium (Gibco), supplemented with 10% fetal bovine serum (FBS; 
Gibco), 50 units/mL penicillin, 50 μg/mL streptomycin and 2 mM L-glutamine at 37°C 
in a 5% CO2 atmosphere. 
 
2.2.6 PEGylation 
Moreover, direct PEGylation of NPs surface is obtained by the formation of an amide 
bond between the their -COOH groups and the -NH2 end groups of the PEG, which is 
labeled with various fluorophores (ie. Cy7 or FITC). In particular, PEG1kDa or 
PEG2kDa labeled are used for these experiments.              
The first step of process provides the activation of the carboxylic groups due to the 
contact between sample (500 µL)  and a solution of EDC (0.02 M) and NHS (0.01 M) 
for 10 minutes in water solution on rotary shaker. After this, a NH₂ -PEG-Dye (1 
mg/ml) is added (4h, at RT, slight rotation). Two washing are carried out  by 
ultracentrifugation (70,000 rpm, 15°C, 10 min) and, finally, the pellet is resuspended in 
a phosphate buffer (pH 6.8). The amount of PEG conjugated to NPs is determined by 
spectrofluorimetric (enspire Multimode Plate Reader PerkinElmer). All measurements 
are performed in triplicate.   
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3. Results and Discussion 
3.1 Functionalization of HA NPs 
Nanomedicine govern the ways in which engineered nanomaterials interact with 
human environment. In particular, the surface modification of the NPs play a key role 
in biomedical sciences. Several clinical results have suggested that the presence of 
specific recognition chemical moieties reduces not only the side effect, especially in 
oncological field, but also enhances the efficacy of nanovectors.                     
For this reason, here, it is reported an example of functionalization of loaded HA NPs 
with specific biomarker (pA20-36) for lymphoma target. In addition, a further 
bioconjugation, mediated by PEG, is explored. 
3.1.1Quantification of carboxyl groups on the surface of crosslinked HA NPs 
The first step for the NPs functionalization is represented by evaluation of the number 
of -COOH groups presented on the surface of the NPs through the application of back 
titration.  
In Figure 17 is showed the graphical representation of the equivalence point obtained 
by titration (HCl-NaOH). The results report that the presence of -COOH groups is 
about 26 nmol/ml of NPs solution. 
 
Figure 17. Representation of the equivalence point obtained 
by back titration.  
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3.1.2 Direct conjugation with peptide pA20-36 and pA20-S 
In the case of direct conjugation with pA20-36 and pA20-S, the results show that HA 
NPs have maintained their stable morphology post reaction.  
 
 
 
Figure 18. Morphological and Optical characterization of  
pA20-S-HA NPs. A) SEM characterization and B) TEM 
image. 
 
3.1.3 Indirect conjugation with peptide pA20-36 
HA NPs are subjected also to indirect conjugation. Also in this case, the results show 
that the morphology of nanovectors is preserved. Here, it is reported SEM analysis of 
intermediate of reaction mediated by STR protein (Figure 19). As it is showed in figure 
19 C, after only 12 h of reaction the presence of STR coating is visible. Moreover, it is 
possible to notice the presence of outer coating, in particular by TEM analysis (Figure 
19 D). 
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Figure 19. SEM images of indirect conjugation with STR 
protein. A) uncoated  HA NPs (control); B) HA NPs after 1 h 
of STR reaction; C) HA NPs after 12 h of STR reaction; D) 
TEM image post indirect conjugation. 
 
The concentration of pA20-36 on the surface of the HA NPs is evaluated by BCA 
assay (Figure 20). In the case of indirect conjugation, a double quantification is 
performed (the conjugation with the streptavidin and conjugation with the peptide).  
In the case of STR conjugation, the yield of process is about 50% while the 
conjugation of peptide reports a yield of 80%. 
In the case of direct conjugation, the yield of process is about 70%.  
- 91 - 
 
 
 
 
Figure 20. Calibration mediated by BSA (range 0 - 40 µg/ml). 
  
3.1.4 PEGylation 
In order to reduce interactions between HA NPs and intra/extracellular components, 
the surface of nanovectors has been coated with PEG, a polymer composed by 
repeating ethylene ether units. In this way, these nanomaterials are protected from the 
the attack by immune system and can circulate in the blood vessels for long time 
allowing their use in drug-delivery and imaging applications.                                    
In this case, after PEGylation reaction, HA NPs have maintained their structural 
integrity as shown SEM, TEM and STED images (Figura 21) .  
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Figure 21. Morphological and Optical characterization of HA 
NPs after their functionalization with NH2–PEG(2kDa)-FITC: 
A) SEM image; B) TEM image and C) Confocal microscope 
image. 
  
 
 
The amount of PEG-FITC conjugated to NPs surface is evaluated by the 
spectrofluorimeter. Polystyrene NPs are used as model (concentration range: 1-150 
µg/ml). The calibration curve for Polystirene NPs is reported in Figure 22, while in 
Figure 23 is reported the calibration for  NH2-PEG(2kDa)-FITC. 
The results obtained by the spectrofluorimeter analysis show that the final yield of the 
PEGylation process is about 65% w/v. This value can be explained on the basis of 
volumetric and steric effects of this polymer.   
A B C 
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Figure 22. Calibration mediated by Polystirene NPs (range 0-
150 µg/ml).  
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Figure 23. NH2-PEG(2kDa)-FITC: Calibration line in the 
range 0-80 nmol/ml.  
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4. Conclusions 
In this section, it is proved that the HA NPs can be successfully functionalized and 
PEGylated without compromising their structure and stability. In fact, the presence of 
carboxylic group on the the surface allows to functionalize these nanovectors with 
suitable biomarkers in order to ensure the tissue specificity and the action of CA. In 
conclusion, the new nanoprobe allows to detect in vivo a speficic pathology, as 
lymphoma, leveraging on active targeting. Further analysis about these nanovectors are 
under investigation, in particular for MRI applications.  
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CHAPTER IV 
Emerging use of nanoparticles in 
diagnosis of atherosclerosis disease  
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1. Introduction 
Cardiovascular disease continues to be the leading cause of death in the Western 
world
192
 and it is caused mainly by atherosclerosis. It is a multifactorial systemic 
disease characterized by arterial wall thickening and rigidity and the formation of the 
characteristic plaques that developed simultaneously in medium and large-sized 
arteries, inducing a blood flow reduction with different complications
193
.  
This inflammatory pathology that has origins in childhood and occurs decades before 
the disease becomes clinically apparent (cardiac arrest, acute myocardial infarction or 
stroke)
194, 195
. The pathogenesis of atherosclerosis has been the subject of many 
scientific works and the major players involved in this process are endothelial cells, 
inflammatory and immune cells (mainly macrophages and T cells), and intimal smooth 
muscle cells (SMCs)
196, 197
. For many years it was believed that the disease was only 
characterized by a passive accumulation of cholesterol in the vessel wall, but, 
nowadays, it is known that the evolution of the lesion is much more complex and not 
fully clarified. In addition, the degree of luminal stenosis is only indirect indicator of 
atherosclerotic process
198
.  At the beginning, our understanding of the atherosclerotic 
pathology is mainly based on postmortem examinations of human coronary arteries or 
analysis of resected surgical specimens from patients who underwent carotid 
endarterectomy.  
In recent years, several imaging techniques, invasive and noninvasive, are available to 
detect and display different characteristics of atherosclerotic lesions of clinical 
interest
5
. The choice and applicability of each imaging technique depend not only on 
its diagnostic efficacy but also on the type of questions being asked. Unfortunately, 
these imaging modalities, neither characterize nor correlate the image parameters with 
histopathological lesion types, which are more clinically relevant. Most of the standard 
imaging modalities characterize some of the morphological and functional features of 
the vascular lesion, but a quantitative evaluation of atherosclerotic disease during its 
natural history and following therapeutic interventions are necessary for understanding   
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the stabilization or progression of the disease and for selecting suitable medical or 
surgical interventions. 
In addition, current therapeutic approaches treat atherosclerosis systemically, not 
locally, which is often associated with decreased efficacy and increased side effects. 
Nanoparticle mediated, targeted delivery of diagnostic agents or therapeutic 
compounds to specific molecules, cells, or tissues represents an innovative approach 
for the diagnosis and treatment of atherosclerosis. Nanoencapsulation in combination 
with targeted delivery may enhance stability and bioavailability of pharmaceutical 
agents, improve their pharmacokinetics, increase detection sensitivity and therapeutic 
efficacy.   
2. Advances in targeting strategies for 
nanoparticles in atherosclerosis imaging 
As described previously, MRI represents the unique technique that combines excellent 
soft tissue discrimination with high spatial resolution without the use of ionizing 
radiation. Nevertheless, this imaging modality is limited by its low sensitivity and 
requires the use of CAs to display the damaged site clearly. This restriction may be 
overcome with a noninvasive molecular imaging approach, considered an in vivo 
equivalent to immunohistochemical techniques and based on a signal imaging element 
encapsulated or conjugated to a carrier that transports a ligand that is then recognized 
by the target molecule. In fact, this strategy can facilitate early diagnosis, has the 
potential to image the pathophysiological process of the disease before the onset of 
symptoms and can be applied to follow the efficacy of therapy. In this scenario, the 
advantage of MRI resides in its ability to provide not only anatomical but also 
functional information quantifying specific biological processes within a single 
imaging modality.  
A variety of molecular targets has so far been successfully employed in preclinical 
models of CVD to identify typical features associated with plaques that are prone to 
rupture. Actually, plaque rupture represents a key process in the initiation of ardiac 
arrest, acute myocardial infarction or stroke syndrome, but given the complexity and 
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heterogeneous nature of the plaques, it could not be identified a biomarker that is able 
to discriminate between patient that needs monitoring (stable plaque) and patient at risk 
of clinical events (unstable plaque).            
Examples of biomarkers are shown below: cell adhesion molecules (VCAM 1 or E-
selectin)
199
, extracellular matrix, lipoproteins, smooth muscle cells, macrophages, 
phosphatidylserine and αVβ3 integrin200, 201.  
At first, the CAs were conjugated with monoclonal antibodies or specific peptides, but 
excellent results are then obtained with NPs that combine a high binding affinity for 
the target zone with the capacity to transport a sufficient amount of a CA. The most 
widely employed NPs are: superparamagnetic iron oxide (SPIO), micelles, liposomes 
dendrimers and polymeric nanoparticles
201-203
. In this section will discuss the recent 
progress in targeting strategies for nanoparticles focused on the recent innovative 
works for nanomedicine.  
 
2.1 Superparamagnetic Iron Oxide Nanoparticles (SPIONs)   
Several MRI strategies to display the atherosclerotic lesions were successfully 
developed using NPs platform
204, 205
. In effect, their chemical, physical and 
pharmacokinetic characteristics and the ability to transport high payloads make them 
highly suited to cellular and molecular imaging of atherosclerotic lesions.  
Generally, two categories of contrast agents are used for molecular MR imaging of 
atherosclerotic plaques: superparamagnetic iron oxide nanoparticles (SPIONs) and 
nanoparticles that incorporate gadolinium (Gd) chelates
202, 206
. SPIONs represent the 
main platform used and are composed of an iron oxide core formed by magnetite 
(Fe3O4) and/or maghemite (γFe2O3) and coated with a polysaccharide, synthetic 
polymer, or monomer, which make them water soluble, prevent their aggregation and 
improve biocompatibility
207. Moreover, the combination “core-shell” influences the 
pharmacodynamic and pharmacokinetic features of the final product. Passive targeting 
of these nanocarriers dependent on the control of parameters such as the surface charge 
and hydrodynamic radius that affect circulation time of the nanoparticles, accessibility 
to tissues, opsonization, and so on. Differently, active targeting takes advantage of 
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nanoparticle’ surface modifications with monoclonal antibodies or peptides207. 
Generally, the term SPIO can be used to refer to: standard SPIO (SSPIO, 60-150 nm), 
ultrasmall SPIO (USPIO, <50 nm), monocrystalline iron oxide nanoparticles 
(MION,~30 nm) and cross-linked iron oxide (CLIO)
208
. Phagocytic cells of 
reticuloendothelial system (RES) take up injected SPIONs spontaneously by   
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endocytosis or phagocytosis allowing a rapid accumulation of these particles at the 
level of the lesion of interest
209
. This system have been characterized as MRI contrast 
agents for the imaging of the plaque inflammation, which represents one the most of 
the features of high-risk atherosclerotic plaques
204
. In particular, Ruehm and 
coworkers
209
 demonstrated that in hyperlipidemic rabbits there is an accumulation of 
USPIOs in plaques with high macrophage content and that this phenomenon induced 
MR signal changes. For this reason, Kooi and colleagues
210
 investigated the detection 
of macrophages in human atherosclerotic plaque. The results showed that the use of a 
USPIO agent, Sinerem® (Guerbet; Ferumoxtran-10), accumulated mainly in 
macrophages in human atherosclerotic lesions prone to rupture, it induced significant 
decrease of signal T2* images obtained 24 hours after intravenous administration but 
not in the images obtained after 72 hours (washout phenomenon). This information 
suggested that USPIO-enhanced MRI is as a promising method for the in vivo 
differentiation between low- and high-risk plaques and additional studies conducted by 
Trivedi et al.
211
 confirmed these preliminary results, suggesting furthermore that there 
is a process of accumulation and excretion of USPIOs. A representative example of a 
study, in which MRI is used to monitor the target site accumulation of USPIOs, is 
published by Tang and colleagues
212
. In summary, the researchers explored whether 
there is a difference in the degree of inflammation between asymptomatic and 
symptomatic patients.The results suggested that one inflamed symptomatic vascular 
bed can be increase the risk of other arterial vessels to become inflamed. Finally, 
preclinical (atheromatous rabbits and ApoE knockout mice) and clinical studies of 
Sinerem® for noninvasive MRI assessment of atherosclerotic plaque inflammation are 
summarized by Tang et al.
213
. 
An example of active targeting, for development of a non-invasive method to detect 
vulnerable plaque prior rupture in vivo, is reported by Smith et al.
214
. In this 
investigation SPIONs consisting of an iron oxide core coated with dextran and 
conjugated to a cellular protein, Annexin V, that recognizes apoptotic cells by specific 
molecular interaction with Phosphatidyl Serine (PS). They tested in two rabbit models 
of atherosclerosis and MRI was performed with a 4.7 T small animal MRI system. The 
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results were confirmed by further histological investigation and vascular targeting by 
the system, SPIONs-Annexin V, was atheroma-specific. In addition, the administered 
dose was significantly lower than the particles without target in the same animal 
model. Therefore, the presence of a biomarker, as Annexin V, can provide additional 
support for the diagnosis of vulnerable plaque. 
Nahrendorf et al.
199
, instead, functionalized MION with linear peptide (VHPKQHR) 
for targeting of the vascular cell adhesion molecule-1 (VCAM-1), which is a biomarker 
expressed at early stages and progression of atherosclerotic lesions. Even in this case, 
the conducted studies in animal models showed that the anatomical area of interest 
became dark (hypointense signal) after the injection of the nanoparticles. Kang and 
colleagues
215
 prepared similar system using CLIO nanoparticles with E-selectin 
antibody fragments to detect E-selectin in endothelial cells. The expression of this 
molecule is induced by an inflammatory cytokine (interleukin-1β) and, as expected, a 
high decrease in T2* signal is present in the treated mice with interleukin-1β compared 
to mice not treated. 
Many research groups have long studied the use of these carriers based on the models 
mentioned above in atherosclerosis detection and several scientific works are reported 
in the literature
216
, but none is currently approved for clinical diagnostic evaluation and 
there are not others in clinical development. 
 
2.2 Polymeric Nanoparticles                         
The strategy to prepare PNs with imaging functionality is to incorporate materials or 
functional groups with some characteristic that makes them a new promising tool for 
the diagnostic. Generally, the CA can be covalently conjugated or physically 
encapsulated within polymeric matrix
41, 43, 49, 217
. In the first case, the molecules with 
imaging properties are connected to polymeric backbone and there may be 
nonhomogeneous distribution and poor loading efficiency of CA on the polymer 
surface. Conversely, in the latter case, the system offers high loading efficiency and 
homogenous distribution of contrast media within the polymeric matrix. Initial 
characterization of polymeric nanoparticles containing gadolinium chelate (Gd-DTPA)   
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as CA for enhanced MRI is reported by Doiron et al.
218
. In this work a water-in-oil-in-
oil double emulsion solvent evaporation technique was used to encapsulate the CA in a 
poly(lactide-co-glycolide) (PLGA) or polylactide-poly(ethylene glycol) (PLA-PEG) 
particle for the transport of MRI agent for the detection of staged atherosclerosis. 
PLGA particles showed negative zeta potentials, while PLA-PEG particles had neutral 
zeta potentials. In vitro experiment showed that cytotoxicity of these particles on 
human umbilical vein endothelial cells (HUVEC) was minimal, while MRI in vitro 
experiment demonstrated that the relaxivity of the PLGA particles is similar to that of 
unencapsulated Gd-DTPA. Recently, Zhang and colleagues
219
 have successfully 
synthesized using water in oil in water method and characterized a new type of 
delivery system based on PLGA. In this case, (Gd)-loaded PLGA nanoparticles show 
on the surface a specific peptide sequence (Arg-GlyAsp-Ser, RGDS) for the detection 
of thrombus at the molecular level. The results of in vitro experiments suggest that 
these molecular probes can be used for detection of thrombus with a longitudinal 
relaxation similar to commercial CAs. 
Recently, our group is focused on the use of biomaterials to improve the healthcare 
services in the field of atherosclerosis diagnosis. Russo et al.
41
, for example, report a 
new Hyaluronic Acid (HA) nanoprobe (35 nm), obtained by a controlled and 
continuous microfluidic process, which entraps CAs for MRI. In a subsequent work, 
the impact that hydrophilic biopolymer networks have on the relaxivity of Gd-based 
CAs has been analysed and the concept of “Hydrodenticity” has been defined to 
describe the ability of these biopolymers to enhance the properties of the metal chelate, 
as reported by Russo et al
43
. Vecchione et al.
49
, instead, describe a core-shell 
architecture for multimodal imaging applications obtained by a modified complex 
coacervation. The relaxivity of Gd-DTPA nanoconstructs is more than four times 
higher than the relaxivity measured for free Gd-DTPA in solution. 
 
2.3 Micelles          
Micelles are self-assembled nanostructures composed by amphiphilic molecules (lipid 
or polymer). They can be made mainly by a hydrophobic core and externally a   
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hydrophilic surface, characteristics that allow encapsulating therapeutic or diagnostic 
agents within the micelles. A first in vitro study is conducted by Lipinski et al.
220
 that 
evaluated the uptake of micelles linked to speciﬁc antibody (immunomicelles) for 
macrophages and containing Gd-DTPA micelles, and a murine model of 
Apolipoprotein E knockout (ApoE KO) is used for ex vivo imaging of lesions. The 
micelles (size <100 nm) are made by lipid monolayers and the results of the 
experiments demonstrated that the immunomicelles are taken up by the macrophages 
compared to untargeted micelle and both micelles and immunomicelles are superior 
CAs compared to the others used in clinical practice. This enhancement is related to 
the content of macrophages, which is associated with plaques vulnerable to rupture. A 
limitation for this study is represented by long acquisition time. A similar approach 
was published by Mulder and coworkers
221
. The obtained results in this work are 
consistent with previously findings that show uptake of immunomicelles in cultured 
macrophages and in ex vivo atherosclerotic aorta
220
. Subsequently, Briley-Saebo et 
al.
222
 conducted a study using micelles containing Gd and antibody (murine or human) 
that bind oxidation-specific epitopes (OSE). The aim of this work was to obtain a non-
invasive in vivo imaging of atherosclerotic plaques rich of OSE by the use of MRI. 
Also in this case, the results show that the active targeting allows to obtain a significant 
signal enhancement using micelles containing a specific antibody and a good 
identification of atherosclerotic lesions. In another work
223
, the same authors changed 
the model previously adopted in order to evaluate the in vivo MRI efficacy of 
manganese (Mn(II)) as molecular imaging probe for OSE. Mn is a paramagnetic metal 
ion, endogenous, and bio-compatible and DTPA is used as the chelating agent. The 
intracellular accumulation in intraplaque macrophages of targeted bio-compatible Mn-
micelles and de-metallation resulting in free Mn resulted in significant efficacy of 
contrast-enhanced MR imaging, allowing the visualization of atherosclerotic lesion 
through a non-invasive method. 
 
2.4 Liposomes                        
Two approaches have been used to prepare liposome-based CAs: (1) encapsulation of   
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the contrast agent into the liposome and (2) chemical conjugation of the MRI probe to 
the liposome membrane. An example of liposomes used for delivery to atherosclerotic 
tissue has been reported by Maiseyeu et al.
224
, where Gd-decorated liposomes enriched 
with phosphatidylserine (PS) were used for imaging of accumulated macrophages at 
atherosclerotic site in ApoE -/- knockout mouse models. This approach allowed a 
signiﬁcant enhancement of atherosclerotic plaque in vivo for molecular 
characterization of high-risk plaques. Based on similar rationale of macrophage 
activity in atherosclerotic lesions, Resen et al.
225
 and Mulder and coworkers
226
 have 
reported the development and contrast-enhanced targeted MR imaging of vascular 
disease associated inflammation using Gd-liposomes.  
Kozlowska et al.
186
, instead, synthesize liposomes loaded with Gd ions using different 
membrane-incorporated chelating lipids and functionalized with monoclonal anti-
CD138 (syndecan-1) antibody for multiple myeloma and non Hodgkin’s lymphoma 
diagnosis. In this case, the use of the polychelating amphiphilic polymer increases both 
the Gd content and the longitudinal relaxivity of the Gd-loaded liposomes as compared 
to commercial CA (Gd-DTPA). 
 
2.5 Dendrimers                            
Dendrimers are a highly significant class of nanosystems that exhibits many attractive 
characteristics and plays an important roles not only as drug delivery carriers, but also 
as imaging agents
227
. In more detail, they are nano-sized structures characterized by a 
controllable multibranched three-dimensional arrangement, globular shape, high 
functionality, small size and low polydispersity
228
. These structures offer three points 
for modification with diagnostic agents: the core, the branching zone and the branch 
extremities
229
. Therefore, active molecules may be encapsulated into the interior area 
or chemically/physically linked onto the nanovector surface.
230
. Their 
pharmacokinetics and pharmacodynamics features are not very clear and thus remain 
to be explored for their bioapplication
228
. In addition, the composition and size of 
dendrimer-based MR imaging agents influences their behavior. The pioneers in this 
field are Kobayashi et al.
231
 that conducted a study about optimization of the   
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performance of dendrimer-based MRI agents in vivo in comparison to Gd-[DTPA] 
using the poly (amido amine) (PAMAM) and diaminobutane core polyaminoamine 
(DAB) for the preparation of MRI contrast agents. They observed that dendrimer-based 
MRI contrast agents are quickly excreted by the kidneys and also able to visualize 
vascular structures better than Gd-DTPA due to less extravasation. Therefore, these 
structures are retained in the body for a prolonged time. Recently, Nguyen and 
colleagues
232
 have synthesized, characterized, and evaluated the MR efficacy of 
manganese (Mn) dendrimers targeted to OSE in murine models. Considering that 
dendrimers can be easily modified to allow for the addition of contrast agents and 
antibodies for targeted delivery, PAMAM-based dendrimers were chosen for their 
ability to load large amounts of Mn and DTPA is chosen as chelating agent. The results 
demonstrated that the administration of the targeted dendrimers allow to obtain a 
significant enhancement of vascular lesions in comparison to untargeted dendrimers. 
The analysis was only qualitative because the observed MR imaging signal did not 
correlate with the histological presence of OSE. 
  
3. Conclusion 
Despite the progress in primary and secondary prevention and the growth of the 
knowledge base of atherosclerosis pathology, the incidence of myocardial infarction 
and stroke continues to remain high. Nowadays, the nanotechnology and the design of 
nanoscale devices seem to be a promising avenue for improving cardiovascular 
outcomes. The examples reported in this work include the use of NPs for MRI as tool 
for non-invasively evaluating atherosclerotic plaques, but their application in 
atherosclerotic field is very limited so far. A future goal in this field is represented by 
the combination of disease-specific biomarkers linked to the suitable carriers with MRI 
imaging modality in order to improve diagnosis and therapy of the atherosclerotic 
lesion. Therefore, it is essential to broaden our current understanding of distinct stages 
of pathological process for the development of novel diagnostic approaches based on   
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these concepts. In the end, potentially harmful effects of these new methodologies must 
be borne in mind.  
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CHAPTER V 
Application of HA NPs in 
atherosclerosis field: preliminary 
results  
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1.  Introduction 
In contrast with conventional imaging approaches, molecular imaging allows to 
evaluate biological features of atherosclerotic plaques in vivo by ensuring prevention, 
screening, diagnosis, and treatment of vascular disorders .                        
Nowadays, as explained in the Chapter IV, imaging tools for early detection of clinical 
atheroma based on the plaque biology are lacking. In fact, despite there is a wide 
knowledge concerning the use of nanotechnologies in cardiovascular disease, the use 
of nanovectors for imaging applications in clinical practice remains limited, not only 
for safety iussess, but also for the heterogeneous nature of atherosclerotic plaques 
which does not allow for a proper segregation the different types of patients. In 
addition, it is known that the old generation of NPs is nonspecific and, actually there is 
no commercialized product, without considering that several studies conducted in 
murine models have significantly highlight that there are different anatomies of 
vascular disease compared to humans. 
In this context, therefore, the combination of specific peptides and nanostructures 
becomes a key factor to interact and/or overcome the biological barriers.  
Unlike other macromolecules, peptides are small entity with higher specificity and 
affinity for target sites and with limited steric constraints. In addition, they can be 
synthesized in the laboratory using different methods, thereby supporting the early 
detection of pathology, moreover due to the high surface area to volume ratio of 
nanovectors, several copies of the ligands can be conjugated. Not for nothing, recently, 
the use of phage display tecnology is under investigation in order to identify new and 
specific peptides ligand for pathology process
1, 2
. 
This technique allows to the synthesized more libraries of heterogenous bacteriophage, 
(viruses that infect bacterial cells) using recombinant DNA technology. The advantage 
of phage display consists principally of binding partner of the peptide sequence that is 
known.  
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Here, it is reported the development of a new probe for molecular imaging 
investigation of cardiovascular disease through the biological knowledge that drive 
plaque progression. 
The experimental design and preliminary studies performed on human atherosclerotic 
plaque and HA NPs are given below.  
 
2. Experimental design 
The ability to functionalize the surface of nanovectors with targeting ligands play a key 
role in real-time diagnosis of vascular diseases. A variety of targeting peptides for 
atheroma have been already tested preclinically, but the search of new and performing 
biomarkers is necessary in order to discriminate a patient at risk from a patient which 
instead only needs to be monitored over time. For this reason, it is decided to test the 
versatility of HA NPs, selecting a suitable peptide,  for MRI imaging of cardiovascular 
disease. 
From a bioengineering perspective, the first step of experimetal design (see Figure 24 
for schematic representation) of new probe consists of selection an appropriate peptide, 
took from random peptide libraries selected based on interaction with specific epitopes, 
able to recognise the site of interest. This process provides for the application of phage 
display tecnology
3
, introduced by Smith and Parmley. Phage-panning procedure for 
selection of peptides with vascular endothelium cellular binding specificity uses an 
M13 random peptide phage display library. After this procedure, different clones are 
chosen for further characterizations. ELISA test are made to confirm specific binding 
between cell line and peptide in vitro. Then, the lead clone with the highest specificity 
is selected, expanded and sequenced to determine the targeting peptide sequence. 
The second part of strategy (Figure 25) provides that loaded HA NPs, synthesized as 
reported in the Chapter III, are conjugated with identified peptide using conventional 
functionalization strategy (amidation reaction). After this step, chemical-physical 
characterizations, relaxation measurements and in vitro/in vivo evaluations are   
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performed in order to establish not only safety but also potential diagnostic 
effectiveness of new probe. 
Finally, the probe is tested for ex-vivo esperiments using human carotid 
endarterectomy (CEA) speciem in order to evaluate diagnostic efficay and at the same 
time the immunohistochemistry of biological sample. 
The effective binding between tissue and probe is also evaluated by electron 
microscope analysis. Special attention is given to the ultrastructural morphology of 
these tissue. 
It is already known, the phage display technology is a laborious method and time-
consuming and, actually, the process of peptide selection is under development. 
For this reason, in this chapter, it is possible to report only preliminary studies 
concerning the manipulation of ex-vivo human tissues for electron microscope analysis 
(Figure 26).  
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Figure 24. Phage display. Principles of protocol used for 
selecting sequences that have affinity to specific biomarker.  
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Figure 25. Experimental design of ex-vivo human plaque 
stage. The markers on human carotid plaque are detected by 
peptide, which are bound to the HA NPs, thereby making these 
plaques “MRI visible. Concomitant immunohistochemistry is 
performed.  
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Figure 26. Human carotid endarterectomy (CEA) speciem 
before electron microscopy analysis.  
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3. Experimental section 
3.1 Materials and methods 
Fibrous and atheromatous plaques are selected from human carotid obtained after 
endarterectomy. This surgical procedure is used to reduce the risk of stroke by 
correcting stenosis in the carotid artery. The surface area of these plaques appears 
yellowish. All the samples (postoperatively) are immediately immersed in 
physiological solution  (4°C, 2 hours) and, then tissue slices fixed following the 
protocols reported below. 
On the basis of analysis, different thikness of cross-sectional slices are cut from each 
lesion. 
All investigated subjects are men (average age of 65 years). 
All procedures are carried out according to EU directives and reviewed by local ethical 
committee. 
 
3.2 Electron Microscopy analysis 
For transmission electron microscopy (TEM), all tissue slices (1 mm x 1 mm) are fixed 
in 0,5% of glutaraldehyde and 4% of paraformaledhyde in 0.1 M Na cacodylate buffer, 
pH 7.4, overnight at 4°C, followed by rinsing in buffer (3 washes, 4°C, 10 minutes). 
Samples are postfixed in osmium tetroxide (4%) and potassium ferrocyanide (2%) for 
1 h at 4°C. This step is followed by three quick changes of 0.1 M Na cacodylate buffer 
over a total of 5 minutes and three quick washes with water solution (4°C, 5 minutes). 
Addition of uranyl acetate (4%) for over-night at 4°C. Three quick washes with water 
solution (4°C, 5 minutes). Treatment with 0.15% tannic acid in water for 3 minutes at 
4°C. Three quick washes with water solution (4°C, 5 minutes). After this, the samples 
are dehydrated and embedded schedule generally 
employed is as follows: 30, 50 and 70%, 1 hour at 4°C; 95% (twice) and 100% (three 
times) EtOH, 1 hour at 4°C; 1:2 Epon:EtOH, 2 hour; 1:1 Epon:EtOH overnight, 2:1 
Epon:EtOH, Epon and two further changes (3 hours), Epon overnight, Epon further 
changes (3 hours), before embedding. The polymerization process is performed at   
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70°C for 72 hours. Ultrathin Cryo-ultramicotome (Leica) sections (80nm) are obtained 
using a diamond knife and collected on copper grids (300 Meshes). All sections are 
analyzed with a TEM ( TECNAI G
2
20 FEI). 
For scanning electron microscopy (Field Emission, FE SEM, Ultraplus Zeiss), small 
tissue blocks of the region of interest are analyzed. All samples are treated according to 
the same protocol reported above for TEM analysis. Here, after the dehydration steps, 
critical point drying (CPD Leica) procedure is applied in order to preserve  the surface 
structure of  samples for next analysis.  Finally, the samples are coated with 20 nm of 
gold using sputter coater and visualized at SEM. 
 
3.3 Nanoparticles investigation 
Different chemical reagents, used during protocols preparation for electron microscopy 
analysis, are tested on unloaded HA NPs in order to estabilish if their morfology and 
stability are preserved during the ex-vivo experiments. 
In particular, 5 aliquotos (500 µl) of unloaded HA NPs in water solution are incubated 
for 1 hour with the following substances:  sodyum cacodylate (0.1 M), Gluteraldehyde 
(2,5% v/v), osmium tetroxide (1% v/v) and paraformadehyde (4% v/v).  
Then, three quick washes with water solution (RT, 5 minutes) are performed. 
The resulting samples are filtered, coating with 10 nm of gold and observed at SEM. 
 
4. Results and discussion 
Atherosclerotic process is activated by alterations of endothelial cells. Thus, it is 
necessary the use of the microscopy in order to visualize the whole intimal surface and 
for better understanding the physiopathology of this disease. 
In this work, scanning microscopy analysis is performed on the luminal surface of the 
human carotid vessel wall (Figure 27). The examination shows that endothelial layer is 
preserved even if it is possible to notice non regular architecture. Several platelets and 
leukocytes adhering to endothelium (Figure 28) and collagen fibrils (Figure 29) are 
visible in all samples.   
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Figure 27. Scanning electron image of trasversal section of 
human carotid artery shows how the wall thickness varies in 
the same tissue. 
 
 
 
Figure 28. Scanning electron image of the surface of 
endothelium. Platetels and leukocytes adhering to endothelium 
are visible. 
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Figure 29. Scanning electron image of subendothelial surface. 
Fibrous cap formed by fibrin proteins and collagen fibrils are 
visible. 
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TEM analysis, instead, show the presence of a high number of macrophage foam cell 
and lipid droplets in all samples investigated (Figure 30). 
 
 
 
 
Figure 30. Transmission electron microscopy showing a 
macrophage foam cell and lipid droplets. 
 
 
 
There are no morphologic alterations of unloaded HA NPs after treatment 
with the principal chemical reagents used during preparation process for 
microscopy analysis (Figure 31).   
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Figure 31. Scanning electron image of unloaded HA NPs 
tested with chemical reagents for 1 hour at RT: A) HA NPs 
control; B) Paraformadehyde (4% v/v); C) Gluteraldehyde 
(2,5% v/v); D) osmium tetroxide (1% v/v) and E) sodyum 
cacodylate (0.1 M).  
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5. Conclusion 
In conclusion, here, it is  report the use of phage display technology to identify 
peptides specific able to target vascular endothelial cells, in particular unstable plaques.  
Further chracterization studies are needed to find and investigate the binding 
specificity of lead peptide to human aterosclerotic tissue and the future application of a 
new probe in the clinical practice. 
Actually, the experimental design has been defined and preliminary tests on biological 
sample and nanovectors are performed. The correlation between the ultrastructural of 
vessel wall and endothelial dysfunction remains to be established. 
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Main Conclusions and Future 
Perspectives  
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Despite the progress in primary and secondary prevention and the growth of the 
knowledge base of pathological processes, the incidence of many diseases to remain 
high. The use of CAs is enormeously increased in the diagnostic practice bacause they 
contribute to better disease detection and characterization, monitoring and thus 
guidance of disease management.                         
Although pharmaceutical coumpounds are widely used in clinical practice, they have 
certain limitations for which have received special attention in the last year. Nowadays, 
the nanotechnology and the design of nanoscale devices seem to be a promising avenue 
for improving clinical outcomes.                            
Contrast media specifically designed for MRI applications are still under development 
and there is a number of technologies involved in the development of nanocarrier 
including in its chemical, physical and biological properties. Despite several efforts 
towards nanocarriers, to choose the most adequate nanocarrier is not obvious for a 
variety of reasons that can simultaneously affect the biodistribution and target of 
nanocarriers. However, there remains a gap between technological advances and 
clinical applications. In this sense, the future prospects of nanotechnology and 
nanomedicine are very promising.                   
However, as stated above, the major challenge consists of development of an 
appropriate paramagnetic CA which shows the following properties: low toxicity, high 
relaxivity and long half-lives, high availability, chemical stability, high magnetic 
moment, and capability for binding the ligands to NPs. In this context, biopolymer-
based CAs can satisfy the required properties. The biological properties of HA, for 
example, make it an ideal candidate to create nanovectors for medical applications, 
although, in order to achieve this, the nanosystems need to be refined to allow an 
enhanced longevity in the physiological environment.  
In particular, in this work is proved that a new generation of more efficient MRI CAs 
can be developed. It can be done using biocompatible and clinical relevant CAs 
without their chemical modification as approved in the clinical practice. The optimal 
conditions to combine a CA with a hydrophilic biopolymer are identified and applied 
to the nanoscale in order to produce nanostructures of biomedical interest with high 
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relaxivity. In particular, stable crosslinked HA NPs encapsulating Gd-DTPA are 
successfully prepared using a method that exploits the use of W/O nanoemulsions as 
templates.                           
The aqueous emulsion droplets are shown to provide a good environment for the 
formation of the NPs and seemed to limit efficiently their size. NPs collected from the 
emulsion droplets using a purification procedure show a size of about 200 nm and 
spherical shape. In addition, WST-1 assay is successfully carried out, proving their 
non-cytotoxicity for murine fibroblast cells.                                              
Thus, the conditions of the herein presented protocol to produce these biocompatible 
NPs offer advantages for the encapsulation of a broad-spectrum of biomolecules and 
provide a potential synthetic route to design a wide range of highly efficient 
nanostructured MRI CAs, letting the surface available for possible functionalization. 
Development of biomarkers for early detection of the most common illnesses (from 
oncology to cardiology)  is another important topic for research using nanotechnology. 
A future goal in this field is represented by the combination of disease-specific 
biomarkers linked to the suitable carriers with MRI imaging modality in order to 
improve diagnosis of specific body lesions. Therefore, it is essential to broaden our 
current understanding of distinct stages of pathological process for the development of 
novel diagnostic approaches based on these concepts.  
In particular, the development of the nanovectors reported in this work includes their 
use for MRI as tool for non-invasively evaluating lymphoma and atherosclerotic 
plaques, but their application in in their respective fields is very limited so far. 
However, from a biomedical point of view, the possibility to tune relaxometric 
properties of CAs by controlling hydrogel structural parameters can pave the way to 
new advancements in the design of nanovectors for diagnosis and therapy. In addition, 
this approach can be easily applied to other types of  hydrophilic polysaccharides and 
further used to design biocompatible NPs with a potential application as drug delivery 
carriers in MRI applications. In the end, potentially harmful effects of these new 
methodologies must be borne in mind. This involves detailed risk assessment of 
products before their use.  
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Project Activities 
This Research activity has been developed in the framework of the project: 
- “CeSMeMo – PONa3_00173”. This Project focuses on the development of 
biomedical products, in particular nanosystems for diagnostics and therapy.  
 
Collaborations 
- IRCCS SDN Gianturco Street, 113, 80143, Naples 
SDN, Diagnostics and Nuclear Research Institute, is an integrated group of specialist 
clinics in diagnostic laboratory and imaging. In vivo MRI analysis are performed in 
this Diagnostic Center. 
Other Activities 
- Award at StartCup Campania with the project “POP-up”, 13thOctober 2017, 
Naples, Italy. 
- Premio Nazionale Innovazione (PNI 2017) with the project “POP-up”, 12 30t 
November – 1th December,Naples, Italy  
- Best Practice with the project “POP-up”, 12 – 13th December,Salerno, Italy  
POP-up is an entrepreneurial initiative aimed at the production and distribution of 
a medical device for the Pelvic Organ Prolapse (POP) in women. POP is a disease 
that seriously compromises the quality of life of patients and currently the applied 
therapy is of a surgical type through the insertion of polypropylene mesh, with not 
always favorable results. The device, patented in 2014, is designed for 
postoperative use and can also be used as urodynamic test prior to surgery to 
improve clinical outcomes.   
